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This study aims to examine the differential gene expression levels of drug 
transporters located on rodent renal proximal tubular cells (PTCs) in 
progressive stages of diabetes. A total of thirty-four male Wistar rats were 
used in this study. These rats were randomly divided into five groups, namely 
baseline (n=6), C1 (n=6), D1 (n=8), C2 (n=6) and D2 (n=8). Baseline group 
was sacrificed after a week of acclimation while D1 and D2 refer to diabetic 
rats induced with a combination of high-fat diet and single dose of 
streptozotocin (STZ) at 35mg/kg. D1 and D2 groups were sacrificed at three 
weeks and eight weeks after administration of a single low dose of STZ 
respectively. C1 and C2 groups were age-matched controls for D1 and D2 
groups respectively.  
A panel of twenty drug transporters which were previously reported to be 
localised on rat kidneys was included in this study. The drug transporters are: 
OAT1 to 3, OCT1 to 3, OCTN1 and 2, OATP1 and 3, OATP-K1, PEPT1 and 
2, CNT1 and 2, MATE1, PGP, MRP2 and 3 and BCRP. These renal drug 
transporters were then analysed for their expression level  
Laser capture microdissection (LCM) was used in the collection of renal PTCs 
in this study. This methodology had been extensively utilised by scientists and 
researchers for the collection of single cell or pure cell populations. This 
technology allows the revelation of specific information of certain cell types 
or populations. As compared to previous laborious and time consuming 
methods, LCM is rapid and straightforward.  
Quantitative real-time polymerase chain reaction (qPCR) is a direct and 
efficient method for the relative quantitation of transporters mRNA expression 
levels. Customisable qPCR arrays containing a panel of selected genes of 
interest are commercially available from biotechnology companies. The qPCR 
array system presents as a convenient tool as each gene-specific primer pair as 
been experimentally tested and verified by the manufacturer. These plates 
come with positive controls, genomic DNA controls, reverse-transcription 
controls, and a panel selected housekeeping genes. These quality control 
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measures allow researchers to be at ease while performing high throughout 
arrays analyses.  
This study had successfully optimised the above-mentioned methodologies to 
generate a good quality RNA suitable for accurate and meaningful gene 
expression analyses. Thus, this protocol will be helpful for researchers who 
share similar interests.  
It was observed that all the rats in D1 and D2 were successfully induced with 
diabetes with the combination of high-fat diet and (HFD) single dose STZ 
(HFD-STZ) administration, their non-fasting plasma glucose remained high 
(above 300mg/dL) from one week post STZ administration till the end of this 
study.  
However, diabetic nephropathy was not successfully induced. The urinary 
total protein, albumin levels and creatinine clearance for diabetic and control 
rats did not have statistically significant difference. Moreover, 
histopathological analysis showed signs of chronic progressive nephropathy in 
both control and diabetic groups, suggesting such nephropathy could be due to 
aging, and not hyperglycaemia. However, transforming growth factor-β (TGF- 
β) which was hypothesised to be a crucial biomarker for tubular injury in 
diabetes showed increased expression levels in PTCs of diabetic rats against 
their age-matched control rats. This observation suggests that tubular injury 
may occur before glomerular damage in diabetic condition.  
In this study, we examined the changes in gene expression levels of 
transporters in terms of effects of maturation and diabetes. It was observed 
that OCT2, OAT2, OAT3, PEPT1, PEPT2, OAT-K1, MATE1, MRP2 and 
MRP3 remained persistently upregulated when control rats were compared to 
the baseline group. On the contrary, OCT1, OCT3, OCTN1, OCTN2, OAT1, 
CNT2, OATP-1, OATP3, BCRP and PGP were downregulated when control 
rats were compared to baseline group, in particular, OCT2, PEPT2, MATE1 
and MRP2 with statistical significances.  
We then looked into the changes in gene expression of drug transporters under 
the combination of maturation and HFD-STZ in rat renal PTCs. While OCT2, 
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OAT2, OAT3, PEPT2, OAT-K1, MATE1, BCRP, MRCP2 and PGP were 
upregulated when both D1 (15-week-old) and D2 (groups were compared to 
baseline group (7-week-old). OCT1, OCT3, OCTN1, OCTN2, CNT2, OATP-
1, OATP-3 and BCRP were upregulated when both diabetic groups were 
compared to baseline group especially OCT2, PEPT2, MATE1 and MRP2 
with statistical significances.  
The effects of HFD-STZ treatment on differential gene expressions in diabetic 
rats were last to assess. OCT3, OAT1, OAT3, CNT1, CNT2, OATP-3, OAT-
K1, BCRP and PGP were constantly upregulated in diabetic rats when 
compared to their age-matched controls at three and eight weeks after HFD-
STZ treatment. On the other hand, OCT1, OCT2, OATP-1 and MATE1 were 
downregulated consistently throughout the treatment period.  
Comparing to previous publications, there were discrepancies in the changes 
of expression levels. This could be due to the different methods used for 
induction of diabetes, the selection of rodent, and the type of cell and/or tissue 
analysed.  
Our study will provide the insight to the changes in drug transporters’ 
expression levels on PTCs during maturation and progressive stages of 
diabetes. These changes in expression levels may be helpful in understanding 






1.1. Drug transporters 
It had been assumed for over 50 years that endogenous compounds and 
xenobiotics enter and exit cells by passive diffusion. However, the discovery 
of P-glycoprotein in the late 1970s revealed an understanding of drug transport 
across cell membranes. Thereafter, countless publications and patents on drug 
transporters had been released and achieved over the next 30 years (1).  Drug 
transporters are also increasingly recognized to be the facilitators for 
regulating movements of essential nutrients such as sugar, amino acids, 
nucleotides, and exogenous compounds across membranes. On top of these 
crucial roles, they too play a part in therapeutic efficacy and toxicity (2).With 
the completion of the human genome sequencing, an estimation of 5% of 
human genes are associated to drug transporters and related  proteins, 
consistent with the biological significance of transporters and their roles in 
maintaining cell homeostasis (3). Much attention had been focused on drug 
transporters located at vital organs such as the brain, heart, intestine, kidneys, 
liver, and placenta which are modulators of drug absorption, distribution and 
elimination (2). 
 
Drug transporters are identified and classified under two superfamilies of ATP 
binding cassette (ABC) and Solute Carrier (SLC). Each superfamily has their 
distinct structural conformations, energy utilisation and transport mechanisms. 
ABC drug transporters are active transporters as they utilise the energy 
released by adenosine triphosphate (ATP) hydrolysis to create concentration 
gradients for the mediation of compounds across membranes (4). On the other 
hand, the SLC superfamily includes passive transporters which allow solutes 
to flow passively down their electrochemical gradients and secondary active 
transporters which enable the solutes to flow against their electrochemical 
gradients via the coupling to transport of a second solute that flows along with 






1.1.1.1. ATP-binding cassette (ABC) transporters 
ABC transporters were first identified and their transport mechanism was 
intensively researched using Escherichia coli as a model in the 1970s (5). 
Figure 1.1 illustrates a typical structure of an ABC transporter comprising two 
distinct domains, transmembrane domain (TMD) and nucleotide-binding 
domain (NBD). The TMD which is embedded in the membrane bilayer is 
made up of alpha helices which are able to recognize a variety of compounds 
and undergoes conformational changes to transport the substrate across the 
membrane. The NBD is found in cytoplasm and is made up of a catalytic core 
domain and a smaller, structurally diverse alpha helical sub-domain that is 
distinctive of ABC transporters. The smaller sub-domain comprises a 
signature motif, known as LSGGQ motif. It allows the binding of ATP that 
enables transporters to utilise the ATP as a direct source of energy for active 
transport for compounds across cell or tissue membranes (6). 
 
 
Figure 1.1 - Structure of an ATP-binding cassette (ABC) transporter. A 
typical ABC. A typical ABC transporter is made up of two distinct domains - 
two units of transmembrane domains and two units nucleotide-binding 
domains (7).  
Members of ABC transporters include the multidrug resistance proteins 
(MRPs), breast cancer resistance protein (BCRP) and multidrug resistance-
associated proteins (MDRs).  These proteins have been demostrated to be 
expressed on membranes of healthy cells, facilitating movements of 
endogenous compounds, as well as a wide range of xenobiotics. As such, they 
play roles in the regulation of drugs absorption and waste elimination from the 
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body. These functions suggest that ABC transporters contribute to cellular 
defense mechanisms (2). 
 
1.1.1.2. Solute carrier (SLC) transporters 
 
In contrast to ABC transporters, the SLC transporters do not possess ATP-
binding sites. They can be uniporters (passive), symporters (coupled) or 
antiporters (exchangers). Passive SLC transporters carry the solutes across 
membranes along the solute concentration gradient. Symporter bind two 
different solutes and transport them in parallel across a membrane. An 
antiporter exchanges one solute for another across a membrane. Both the 
symporter and antiporter utilise the energy stored in the electrochemical 
concentration gradients of the ions, therefore they are also known as secondary 
active transporters. These transport mechanisms are illustrated in Figure 1.2.  
 
 
Figure 1.2 - Illustration of transport mechanisms of Solute-Carrier (SLC) 
transporters. SLC transporters utilise three different transport mechanisms - 
Passive, coupled or exchanged transportations (8).  
This huge superfamily of more than 350 members is able to transport 
numerous endogenous and exogenous compounds across plasma membranes 
(8). Examples of SLC transporters are organic anion transporters (OATs), 
organic cation transporters (OCTs), peptide transporters (PEPTs) and 
multidrug and toxin extrusion transporters (MATEs) which play significant 





1.1.2. Vectorial drug transport 
A polarized cell surface is made up of an apical and basolateral membrane 
which is separated by a tight junction. The membrane on which the drug 
transporter is located is crucial in the determination of the net transcellular 
transport and eventually, controlling the pharmacokinetic profiles of drug 
substrates (9). Drug transporters function differently based on their locations 
on different tissues. For example, rat OATP1 when is expressed on the 
basolateral membrane of hepatocytes mediates the uptake of anionic 
compounds, and functions to reabsorb substrates from urine when expressed 
on the apical membrane of renal epithelia. However, rat OATP1 works in 
renal secretion rather than reabsorption when expressed on renal basolateral 
membrane (9). In the epithelial cells of the small intestine, kidney urinary 
tubular cells, the choroid plexus forming the blood-cerebrospinal fluid barrier 
(BCSFB), the blood side corresponds to the basolateral side and lumen or 
cerebrospinal fluid side corresponds to the apical side. In the case of blood-
brain barrier (BBB), the blood side matches the apical side while the brain side 
matches to the basolateral side. Movement of endogenous and exogenous 
compounds mediated by drug transporters expressed on both apical and 
basolateral membranes will result in vectorial transportation.  
 
1.1.2.1. Intestine 
In small intestinal epithelium, uptake transporters such as PEPT and IBST are 
expressed on the apical membrane. These transporters play a role in the uptake 
of small peptides and bile salts and then secrete them into the blood circulation 
(10, 11). On the other hand, efflux transporters such as MDR1 (12), MRP2 
(13) and BCRP (14) are expressed on the apical membrane for the elimination 
of xenobiotics into the systemic circulation (15). MRP1, MRP3 and OCT1 
were reported to be expressed on the basolateral membrane to aid in the 
elimination of their respective substrates from blood circulation into the 
intestinal lumen (16-18).  
 
1.1.2.2. Kidneys 
Many uptake and efflux transporters are located on the basolateral and apical 
membrane respectively of the kidney epithelium. For example, OAT1, OAT3 
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and OCTs were studied to be expressed on the renal basolateral membranes 
which take up organic anionic and cationic compounds (19). PEPTs, rat 
OAT2, OATP1 and OAT-K1 were expressed on the apical membrane of the 
kidney epithelium (20-22). OATP1 and OAT-K1 were studied to be 
bidirectional transporters, suggesting that they may play dual roles in both 
reabsorption and secretory pathways for their substrates (23, 24). Efflux 
transporters, MRP2, MRP4 and MDR1 were also reported to be expressed on 
the apical membrane (12, 25, 26).  
 
1.1.2.3. Liver 
Hepatocytes are highly polarized cells accountable for the vectorial efflux of 
water. Uptake transporters such as NTCP, OAT2, OATP and OCT1 are 
located on basolateral membrane and efflux transporters such as MRP2, 
MRP3 are expressed on the apical membrane. The active and unidirectional 
efflux of organic anions into the bile via MRP2 and the BSEP is able to create 
a high osmotic gradient across the cell membrane to facilitate entry of water 
from blood into the bile (27). 
 
1.1.2.4. Blood-Testis and –Placental Barrier 
Sertoli cells, also known as the ‘nurse’ cells found in testes express MRP1 on 
the basolateral membrane, and MDR1 and BCRP on the apical membrane 
(28). Such localisations of drug transporters restrict the entrance of toxic 
compounds from the systemic circulation (29). In the placenta, MDR1, MRP2 
and BCRP are located on the apical membrane of placental 
syncytiotrophoblast while MRP1 and MRP3 are expressed on the basolateral 
membrane of such cells. Although the exact roles of these efflux transporters 
are yet to be determined, it was suggested these transporters may play a role in 
the protection of the fetus from toxins in the maternal circulation (29). 
 
1.1.2.5. Blood-brain barrier and blood-cerebrospinal fluid barrier 
In BBB, efflux transporter, MDR1 is located on the apical membrane of brain 
capillary endothelial cells. MDR1 participates in the efflux of lipophilic 
compounds (30). In rat BBB, OATP2 is found on both apical and basolateral 
membranes. This bidirectional transporter plays a role in the traffic of organic 
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anions (31). BCRP was studied to be expressed on the apical membrane of 
human BBB. It was postulated that BCRP may restrict the entry of cytotoxic 
compounds, sulfated conjugates of therapeutic drugs and hormones into the 
brain (32).  In rat blood-cerebrospinal fluid barrier, MDR1, PEPT2, OAT3 are 
expressed on the apical side and MRP1 and MRP1 and OATP2 are located on 
the basolateral membrane (33-35). It was recently reported that subcellular 
localization of MRP4exists in the apical membrane of BBB and apical 
membrane of blood-cerebrospinal fluid barrier. This heterologous localization 
(both facing the blood side) may play crucial defensive role against toxic 





1.1.3. Regulation of drug transporters gene expression 
The expression levels of drug transporters can be altered under physiological 
and pathophysiological conditions. These changes will affect to the transport 
activity of such transporters, and consequently, the pharmacokinetics of 
substrate drugs. This regulation of drug transporter expression levels in 
response to endogenous and exogenous compounds may occur at various 
levels such as transcription, mRNA stability, translation, and post-translational 
modification. The change at transcriptional level is especially important as 
changes in drug transporters activity level are dynamically regulated by 
alteration in levels of mRNA expression (37). Aging, gender, genetic 
variations and diseases are examples of physiological and pathophysiological 
conditions and their impact on the expression levels of drug transporters is 
elaborated in subsequent sections.  
1.1.3.1. Aging (Maturation) 
OATP1A1, OATP1A4, OATP1A6 are known to be rodent organic anion 
transporters. These transporters were found to have lower expression levels 
before birth but their hepatic RNA levels increased as the mice matured till 45 
days after birth (38). Similar trend was observed in the hepatic OCT1 for 
mice. Hepatic OCT1 was not detected  two days before birth but expression 
level gradually increased till 45 days after birth (39).  Renal OCT1 and OCT3 
shared resemblance in expression trends. There is no expression level two 
days before birth but subsequently, increase in mRNA levels for both renal 
transporters was observed (39). There is currently very little knowledge about 
the mechanisms responsible for the developmental expression of the drug 
transporters. It was suggested that the sudden increase in some drug 
transporters expression at birth could be attributed to hormones or stress at 
birth, changes in diet from mothers’ milk to chow, puberty and eventual 
maturation.  
1.1.3.2. Gender 
In the adult male and female mice, differential gene expression of drug 
transporters was observed in both genders. To state a few examples, 
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OATP1A1 and BCRP in liver and OATP1A1 and OCT1 in kidney showed 
higher expression levels in adult male mice than their female counterparts. 
(38, 39) These gender differences in drug transporter gene expression levels 
could be due to regulation of sex hormones (androgens and estrogens).  
1.1.3.3. Genetic variation 
The effects of genetic variation on the drug transporters’ expression levels had 
been widely studied. For example, the V189I variant of  CNT1 and C385del 
and S546P variants of CNT3 were demonstrated to have a reduction in 
function for both transporters (40-42). It was reported that R412G, R768W, 
S789F, R1150H, I1173F and Q1382R variants of MRP1 were associated wit 
reduced transporter function (43-45). Pharmacogenetic research on drug 
would enhance the understanding of interindividual variability in drug 
response and toxicity. These data will be extremely useful for personalised 
drug therapy.  
1.1.3.4. Disease 
It has been well established that drug transporters’ expression levels can be 
altered under diseased conditions, therefore may be crucial in determining the 
pharmacokinetics and pharmacodynamics of a drug. For example, in the 
SLC47A1 (MATE1) knockout mice model, an increased concentration of 
metformin was observed in the livers, causing lactic acidosis (46). Rodent 
CNT1 and CNT2 showed reduction in expression levels under diabetic 
condition induced by STZ injection (47). The above-mentioned examples 
illustrate the impacts alterations in drug transporters expression levels have on 




1.2. Diabetes Mellitus  
1.2.1. Current trends 
Diabetes mellitus is a metabolic disorder characterized by the inability of the 
body to clear glucose present in blood due to the lack of response to actions of 
insulin or lack of insulin secretion. Insulin is a hormone produced by the beta 
cells in pancreas which regulates the circulatory glucose levels and cellular 
glucose uptake. There are two major types of diabetes, namely type 1 and type 
2. All forms of diabetes impose a risk of long-term complications such as 
cardiovascular diseases, stroke, retinopathy, nephropathy, neuropathy and 
amputations (48). 
The World Health Organization had declared diabetes mellitus a worldwide 
epidemic in 2000 and there was a shocking prediction of having 366 million 
diabetic patients in 2030 from 171 million patients in 2000. This revelation 
could be the consequences of urbanisation where food is conveniently within 
reach and increasingly sedentary lifestyle due to advent of advanced 
technologies and automation at work. 
Type 1 diabetes mellitus (T1DM) is also known as insulin dependent diabetes 
mellitus. As its name suggests, the treatment of T1DM is reliant on insulin 
treatments. This is because T1DM is an autoimmune disorder which the 
body's T cells attack beta cells, resulting in the failure of the body to secrete 
insulin. With the use of insulin treatment, patients respond well and are able to 
maintain normal blood glucose level.  
Type 2 diabetes mellitus (T2DM), formerly known as insulin independent 
diabetes mellitus is the more common type of diabetes. Contrary to T1DM, the 
patients suffering from T2DM are characterized by high blood glucose in the 
context of insulin resistance and relative insulin deficiency. In the earliest 
stage of diabetes, there are decreased levels in insulin-induced glucose in both 
skeletal muscle and liver. This is because the beta cells compensate the 
increased glucose levels by secreting more insulin to maintain a normal blood 
glucose level. However, insulin resistance occurs due to persistent 
hyperinsulinemia, causing the destruction of beta cells and eventually, the 
onset of diabetes (49). Insulin treatment and oral medications are often used as 
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therapies on top of adhering to strict diet. In addition, weight loss programmes 





1.2.2. Kidney physiology 
The fundamental role of the kidneys is to eliminate waste from the body. The 
kidneys play important roles in acid-base homeostasis, osmolality regulation, 
blood pressure regulation, and hormone secretion. There are approximately 2 
million nephrons in both kidneys and they are the urine-producing functional 
structures of the kidneys. Each nephron is made up of glomerulus which is 
connected to a long tubular segment consisting renal PTCs , Loop of Henle, 
and distal tubule. The major functions of these nephrons are the reabsorption 
of water and small molecules from filtrate into the blood, and the secretion of 
wastes of blood into the urine. The kidney's ability to perform its functions 
rely on the three essential functions, namely filtration, reabsorption and 
secretion (51). 
1.2.2.1. Filtration 
In the nephron, blood is filtered through the walls of glomerular capillaries 
and Bowman's capsule. This filtrate contains water, sodium potassium and 
chloride ions, glucose and small proteins. As soon as the filtrate reaches the 
Bowman's capsule, it will flow through the lumen of nephron into the 
proximal tubular cell. It is important to note that no red blood cell will be 
filtered except for the molecules mentioned above. Therefore, there should be 
no detection of blood in the urine under normal physiological conditions (51).  
 
1.2.2.2. Reabsorption 
Once the filtrate enters the PTCs, small molecules such as sodium potassium 
and chloride ions and glucose found in the filtrate get reabsorbed. 
Reabsorption is a two-step process with the active or passive extraction of 
substances from tubule fluid into renal interstitium, and then into the 
bloodstream. Drug transporters play roles in the reabsorption of small 
molecules, for example sodium-glucose transport proteins which are located 
on the renal PTCs are intensively studied to contribute to renal glucose 





Secretion is the process of transporting solutes into the renal tubule so that 
they can be excreted in the urine. Tubular secretion is an active transport 
process which requires the drug transporters to mediate the transport of 






1.2.3. Renal drug transporters 
The drug transporters which are expressed on the basolateral and apical 
membranes of tubular epithelium are often expressed in the proximal tubular 
and they work hand in hand to regulate drug elimination. For a compound to 
be secreted into the lumen, at least two transporters are required: one 
transporter to be located at basolateral and apical membranes each to accept 
the compound from the blood and to mediate the exit of compound to tubule 
fluid respectively. Figure 1.3 illustrates a few examples of the renal drug 
transporters studied to be expressed on PTCs (52). Table 1.1 lists the twenty 
drug transporters to be studied in current study. These transporters were 
previously studied to be expressed in rodent kidneys. They will be individually 
elaborated below.  
 
Figure 1.3 – Examples of drug transporters expressed on renal proximal 
tubular cell. It shows a few examples of renal drug transporters which are 
located on the apical and basolateral membranes of a renal proximal tubular 
cell. These transporters function as an influx and/or efflux mediators to 




Table 1.1 - List of renal drug transporters studied in current study.  
Gene Name Gene Symbol Description 
OATP1 SLCO1A1 Solute carrier organic anion transporter family, 
member 1a1 
OATP3 SLCO1A5 Solute carrier organic anion transporter family, 
member 1a5 
OAT-K1 SLC21A4 Kidney specific organic anion transporter 
OCT1 SLC22A1 Solute carrier family 22 (organic cation 
transporter) member 1 
OCT2 SLC22A2 Solute carrier family 22 (organic cation 
transporter) member 2 
OCT3 SLC22A3 Solute carrier family 22 (extraneuronal 
monoamine transporter) member 3 
OCTN1 SLC22A4 Solute carrier family 22 (organic cation 
transporter) member 4 
OCTN2 SLC22A5 Solute carrier family 22 (organic cation 
transporter) member 5 
OAT1 SLC22A6 Solute carrier family 22 (organic anion 
transporter) member 6 
OAT2 SLC22A7 Solute carrier family 22 (organic anion 
transporter) member 7 
OAT3 SLC22A8 Solute carrier family 22 (organic anion 
transporter) member 8 
PEPT1 SLC15A1 Solute carrier family 15 (oligopeptide 
transporter) member 1 
PEPT2 SLC15A2 Solute carrier family 15 (oligopeptide 
transporter) member 2 
CNT1 SLC28A1 Solute carrier family 28 (sodium-coupled 
nucleoside transporter) member 1 
CNT2 SLC28A2 Solute carrier family 28 (sodium-coupled 
nucleoside transporter) member 2 
MATE1 SLC47A1 Solute carrier family 47 member 1 
BCRP ABCG2 ATP-binding cassette, sub-family G (White) 
member 2 
PGP ABCB1B ATP-binding cassette, sub-family B 
(MDR/TAP) member 1b 
MDR2 ABCC2 ATP-binding cassette, sub-family C 
(CFTR/MRP) member 2 
MDR3 ABCC3 ATP-binding cassette, sub-family C 






1.2.3.1. Organic anion transporters (OAT) 
OAT1 is strongly expressed in the kidneys, specifically at the basolateral 
membrane of the renal PTCs. It is also expressed in the brain, choroid plexus, 
spinal cord and iris-ciliary body. Substrates of OAT1 include endogenous 
compounds such as medium chain fatty acids, α-ketoglutarate, citrulline, 
cAMP, cGMP, prostaglandins, urate, and acidic neurotransmitter metabolites. 
OAT1 can also transport exogenous compounds such as antibiotics, antiviral 
drugs, histamine receptor subtype 2 antagonists, diuretics, and non-steroidal 
anti-inflammatory drugs. The human OAT1 participates in the renal excretion 
of urate and organic anions and also participate in the renal reabsorption of 
organic anions across the basolateral membrane (53). Srimaroeng et al 
observed a reduction of OAT1 expression level under diseased conditions such 
as endotoxemia, fever, ischemia-reperfusion, renal insufficiency, and ureter 
obstruction. Therefore, this change could affect the pharmacokinetics of drugs 
and substrates of OAT1 (54). 
Contrary to OAT1, OAT2’s expression is weak in kidneys but is abundantly 
expressed in the liver. It is found in low expression levels in the testis, ileum 
and uterus. It is interesting to note that the differences in expression levels 
were observed in different genders. OAT2 expression is high in liver and low 
in kidneys in male rodents, whereas the opposite was observed in the female 
counterparts (55). The human OAT2 was located at the basolateral membrane 
of renal PTCs while rodent OAT2 was observed to be on the apical membrane 
of PTCs (53). While glutamate and urate are OAT2’s physiological substrates, 
the transporter also mediates a wide range of endogenous substrates including 
L-ascorbate, orotic acid, a wide range of purines and pyrimidine nucleobases, 
nucleosides and nucleotides, hypoxanthine, prostaglandin, allopurinol and α-
ketoglutarate. The human OAT2 also transports xenobiotics such as salicylate, 
erythromycin, tetracycline, and allopurinol to name a few. Similar to OAT1, 
OAT2 functions in the secretion of urate and other organic antions in the 
human kidney. OAT2's genetic variations were identified in the coding region 
of OAT2 which may affect the expression level or functions of OAT2, thus 
altering the concentrations of glutamate and increase urate concentrations in 
the serum. Furthermore, the pharmacokinetics of anionic drugs including 
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metabolization in liver, biliary excretion and/or renal excretion may be 
affected (54). 
High expression of the human OAT3 was observed in the kidneys and weakly 
expressed in the spinal cord, choroid plexus, eye, adrenal tissue, stomach, 
colon, mammary gland, blood, liver, skeletal muscle and tumour cells. OAT3 
expression level was studied to be threefold higher compared to OAT1, 
tenfold higher than OAT2, suggesting OAT3 to be the most highly expressed 
among its family members. Similar to OAT1 and OAT2, OAT3 was localised 
at the basolateral membrane of PTCs (19). On top of transporting similar 
substrates as OAT1 and OAT2,  OAT3 can also mediate the transport of 
antibiotics, antiviral drugs, activated form of oseltamivir, H2 receptor 
antagonists, diuretics, nonsteroidal anti-inflammatory drugs, cholesterol 
lowering drugs, antihypertensive drug quinaprilat, antidiabetic drugs and 
neuroprotective drugs (53). Human OAT3 is studied to be important for the 
renal secretion of metabolites such as urate and indoxylsulphate and organic 
anionic drugs. Brady et al commented that a loss of OAT3 during maturation 
may cause osteosclerosis in mice, thus influencing the calcification of bone 
(56). Both protein and mRNA expression levels were reduced for OAT1 and 
OAT3 in adenine-induced chronic kidney failure. Benzylpenicillin, a common 
substrate for both OAT1 and OAT3 was used to evaluate the functions of 
these transporters located at the basolateral membranes and was shown a 
reduction in uptake clearance in rats with adenine-induced chronic kidney 
failure when compared to their healthy counterparts (57). Thus, selection of 
drug therapy should be carefully considered with the above mentioned genetic 
alteration or variation which may affect the pharmacokinetics of drugs which 
are mediated by OATs.   
1.2.3.2. Organic cation transporters (OCT, OCTN) 
OCT1 was first cloned from the rat in 1994 and subsequently cloned in human 
and other species. OCT1 is abundantly expressed in the rat kidneys but weakly 
expressed in the human kidneys. While OCT1 is localized at the basolateral 
membrane of rodent renal PTCs, it is localised at the luminal membranes of 
human renal PTCs. Thus, OCT1 is involved in the reabsorption of 
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ultrafiltrated cations in kidneys (58). OCT1 mediates the transport of a wide 
range of drugs such as antidiabetic drug metformin, antiviral drugs 
lamuvidine, acyclovir and ganciclovir, antiparasitic drugs pantamidine and 
furamidine, antineoplastic drugs oxaliplaton, picoplaon and substrates like 
carcinogens aflatoxin B1 and ethidium bromide (59). The variability in OCT1 
expression can be determined by genetic and epigenetic factors including 
different expression during disease states. It was studied that single nucleotide 
mutations are able to change the expression, thus affecting the transport 
activity substrate selectivity (60). A recent study revealed a correlation 
between OCT expression levels in chronic myeloid leukoma cells and the 
therapeutic effect of cytostatic drug imatinib (61). This could suggest 
expression and transport activity of OCT1 may affect the pharmacokinetics of 
drugs that are transported by OCT1.  
 
OCT2 is mainly expressed in the kidneys where it is localised at the 
basolateral membrane of renal renal PTCs  (19). Similar to OCT1, it covers a 
wide range of substrates including antiparkinson drugs, antineoplastic drugs, 
histamine H2 receptor antagonists, antiviral drugs, diuretic and antidiabetic 
drug (58). Human OCT1 was studied to mediate the renal excretion of many 
organic drugs for example antiallergic drug cimetidine where it participates in 
renal reabsorption of choline and other organic cation substrates such as 
dopamine in the renal PTCs  (62). Lin et al had observed OCT2 genetic 
mutations which resulted in impaired functions may cause a reduction in renal 
excretion of cationic drugs and passage of drugs across the BBB (63). The 
renal expression of OCT2 is downregulated during acute and chronic renal 
failure, leading to alterations in pharmacokinetics and nephrotoxicity of OCT2 
substrates (64). A similar observation was made by Ciarimboi et al that 
nephrotoxicity and ototoxicity of anticancer drug cisplatin correlate with the 
expression and activity of OCT2 in the kidneys and inner ear (65). Brett et al 
demonstrated a reduction in OCT1 and OCT2 protein expressions in 
experimentally-induced diabetes (65mg/kg STZ) in SD rats (66). 
The tissue expression of OCT3 is ubiquitous, expressing in almost all parts of 
the body tissue, heart, skeletal muscle, brain, small intestine, liver, lungs, 
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urinary bladder, mammary gland, cornea, skin, blood vessels, tumour cells and 
kidneys. However, OCT3 expression levels are high especially in the brain, 
liver and heart but weakly in the kidneys (59). OCT3’s functions are 
especially important for substrates which are not transported by OCT1 or 
when OCT1 is inhibited by specific drugs (67). Genetic mutations are able to 
impair the expression or function of human OCT3 causing the reduction in the 
hepatic excretion and materno-fetal passage of OCT3 specific cationic drugs, 
thus suggesting that such genetic defects may alter the pharmacological effect 
of antidiabetic drugs (68).  
Similar to its family members, OCTN1 is widely expressed throughout the 
body tissues, such as kidneys, ileum, colon, heart, brain, lungs, testis, spleen, 
bone marrow, skin, cornea and even tumour cells. OCTN1 is located in the 
brush-border membrane of renal renal PTCs . It is able to mediate transport of 
many substrates such as organic cations, anticancer drugs, anticholinergic 
drugs and zwitterions ergothioneine and L-carnitine (58). OCTN1 knockout 
mice model showed an increased sensitivity to intestinal inflammation after 
ischemia when compared to wildtype mice. This observation led to the 
correlation of OCTN1 mutation with Crohn’s disease to the altered 
intracellular ergothioneine concentrations (69). Therefore, drugs which are 
able to change OCTN1 expression levels may be potential therapeutic options 
for treatment of Crohn’s disease or diseases related to OCTN1 (53). 
 
Tissue distribution of OCTN2 is very similar to OCTN1 and it is also localised 
in the brush border membrane of renal renal PTCs. Human OCTN2 is a high 
affinity Na+-L-carnitine cotransporter which is able to mediate the transport of 
carnitine. It is also a polyspecific, Na+-independent organic cation transporter 
which transports organic cations in both directions across the cell plasma 
membranes (58). Human OCTN2 participates in the absorption of L-carnitine 
and other organic cations in small intestine and reabsorption of the same 
substrate in the renal renal PTCs  (53). Similar to the rest of the family 
members, genetic variations of OCTN2 may affect the expression levels and 
functions of OCTN2. These reductions in OCTN2 expression levels were 
studied to cause systemic carnitine deficiency, increase risk for various 
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conditions: heart failure in hypertonic patients, inflammatory bowel disease 
(IBD), and influenza-associated encephalopathy and changes in the efficacies 
of drugs (58). Therefore, drugs or supplements which are able to increase 
OCTN2 expression levels may potentially aid in the treatment of the diseases 
or illnesses associated with OCTN2.  
1.2.3.3. Organic anion-transporting polypeptide (OATP, OATP-K1) 
OATPs are sodium-independent transport systems, which utilise the anion 
exchange, coupling the cellular uptake of organic compounds with the efflux 
of biocarbonate, glutathione and its conjugates and also a wide spectrum of 
amphilipathic organic compounds such as bile salts, steroid hormones and 
conjugates, thyroid hormones, organic cations and exogenous compounds such 
as HMG-CoA reductase inhibitor pravastatin, antihistamine fexofenadine (70). 
Most OATPs are expressed in many tissues such as the brain, lungs, heart, 
intestines, kidneys, placenta, and testes and abundantly in liver (71). They play 
roles in the uptake of drugs from blood to hepatocytes. Depending on the 
xenobiotics’ characteristics; these transporters may play important roles in the 
systemic clearance of the drug. For example, OATPs which are expressed in 
kidneys function to excrete drugs into urine. Similarly, these transporters may 
affect drug distribution in the brain and central nervous system (72). 
Rat OATP1A1 was the first member of the OATP gene superfamily to be 
identified via expression cloning using the Xenopus oocyte system.  In the 
kidneys, rodent OATP1 was studied to be expressed in the brush border apical 
membranes of the S3 segment of PTCs (71). Kanai et al suggested rodent 
OATP1 was the main efflux route of glucocorticoids and spironolactone, 
because none of the cloned OATP members appeared to have homology 
similarity with OATP1 (73) (74). Another member of OATP family was 
identified in 1996 and was named OAT-K1. It is solely isolated in the rat 
kidneys at the PTCs and medullary collecting ducts (74). Using in vitro assays, 
it was studied that the substrates of OAT-K1 were folic acid and its 
derivatives, such as methotrexate (75) (24) (76). Based on this finding, 
methotrexate was used to study the role of OAT-K1 in urinary excretion. A 
significant increase in plasma methotrexate concentration and a drop in its 
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renal clearance were observed, leading to a longer exposure to methotrexate. 
A reduction in OAT-K1 mRNA expression levels in nephrectomised rats was 
also noted, suggesting a relationship between OAT-K1 expression levels and 
methotrexate plasma concentration and clearance rate. Therefore, OAT-K1 
plays an important role in the renal secretion of methotrexate (77). These 
findings form the fundamental basis to study the regulation of anion drugs by 
transporters under pathophysiological conditions.   
1.2.3.4. Peptide transporters (PEPT) 
It was long established in the 1980s that peptides and peptide-like drugs were 
transported into cell vesicles by a process that was coupled to the movement 
of protons down an electrochemical proton gradient via the brush border 
membrane vesicles studies. Subsequently, PEPT were cloned and studied with 
regards to their expression, localisation and functionality (78).  In vivo studies 
showed PEPT1 aids in the traffic of a broad range of dipeptides, tripeptides 
and peptide-like drugs like cefadroxil, enalapril and valacyclovir in oocytes, 
rabbits and hamster cell line (79) (80) (81). However, there were limited 
studies on PEPT2 as compared to PEPT1 although the former transports 
similar substrates as the latter (78). PEPT1 is abundantly expressed on the 
epithelial cells of small intestines and kidneys. It is localised in the renal 
proximal tubular cell, specifically at the brush border membranes of S1 
segments. It was also studied to be expressed in the pancreas, bile duct and 
liver. PEPT2 was also expressed in kidneys but localised to S3 segments. 
Neither transporter appears to be present at other parts of the nephron, 
indicating their specific role in renal reabsorption (82). Many studies had been 
conducted to provide better understanding of the functions of PEPT1 and/or 
PEPT2 with regards to cellular influx of substrates from apical surfaces. 
However, no clone is available to resolve the precise nature of PEPT1 and 
PEPT2 although functional studies indicated a distinct difference in transport 
systems occurring in intestine, kidney and choroid plexus between both 
peptide transporters (78) (83).  
PEPT1, encoded by SLC15A1 was studied to have two rare variants which 
altered transporter activity. The P586L variant reduced the transport capacity 
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of GlySar in transfected HeLa cells while the second variant, F28Y showed a 
reduction in GlySar uptake in transferred HEK293 cells (84) (85). PEPT2 
which is encoded by SLC15A2 showed a rare R57H variant resulted in a 
complete loss of function for GlySar uptake in transfected HEK293 cells and 
Xenopus oocytes (86).   
Studies have shown that diets are able to influence PEPT1 expression and 
activity as well. For example, upregulation of PEPT1 protein in duodenal, 
jejunal, ileal segments in wildtype mice was observed after 16 hours of 
fasting, leading to an increase in oral absorption of glycylsarcosine in such 
mice. This observation was not evident on SLC15A1 knockout mice (87). 
PEPT1 was suggested to play an important role in IBD through studies 
showing an increased expression level of PEPT1 in IBD. PEPT1 was 
suggested to participate in the intestinal uptake of chemotactic bacterial 
peptides in colon to an aggravated inflammatory response (88) (89). With 
respect to kidney diseases, both PEPT1 and PEPT2 expression levels were 
reduced in kidneys 16 weeks of nephrectomy in male rats (90). In chronic 
renal failure induced by adenine, PEPT1 mRNA transcripts were also reduced. 
PEPT2 on other hand did not show significant difference (57). 
1.2.3.5. Concentrative nucleoside transporters (CNT) 
Endogenous nucleosides are important precursors of nucleic acid synthesis 
which are essential for growth and metabolism. CNTs were capable of 
transporting these nucleosides and most of their hydrophobic analogues with 
low membrane permeability. CNT1 and CNT2 have higher affinity for 
pyrimidine and purine compounds respectively. The CNTs play crucial roles 
in maintaining total body homeostasis of nucleosides, especially for CNTs 
which are localised on absorptive and excretory organs (47). CNT1 was 
identified in 1994 from rat jejunal cDNA library by expression cloning using 
Xenopus oocytes system. Its human homolog, hCNT1 was later isolated from 
human kidney. Both human and rat CNT1 were studied to be expressed 
predominantly in the liver and kidney and weakly in other parts of the body. 
Human CNT2 was first isolated from rat liver and was widely expressed in 
heart, liver, brain, lungs, placenta and intestines but rat CNT2 had low 
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expression levels in kidneys as compared to CNT1 (91). Cells take up purines 
and pyrimidines via two pathways, de novo biosynthesis and salvage pathways 
and CNTs primary role is to facilitate the cellular uptake of such natural 
nucleosides required for nucleotide synthesis in salvage pathways. Salvage 
pathways are important in some organs where tissues are unable to undergo de 
novo synthesis. Therefore, CNTs are particularly important in such cells (92). 
Silvia Rodriguez-Mulero et al demonstrated that STZ induced diabetes led to 
the alteration of CNTs mRNA transcripts. Wistar rats were injected with a 
high dose of STZ for the induction of diabetes and nephron segments were 
isolated three weeks after the induction of diabetes. Consequently, the rCNT1 
and rCNT2 gene expression levels on renal PTCs were reduced. However, 
rCNT1 expression level increased while rCNT2 mRNA transcripts were 
reduced in the glomerulus. This study not only confirmed the localisation of 
rCNT1 and rCNT2 on rat renal epithelial cells but also suggested the 
involvement of these transporters in other physiologic roles (47). 
1.2.3.6. Multidrug and toxin extrusion protein (MATE) 
MATE1 was first identified as an orthologue of the bacterial MATE family in 
2005. Both human and rat MATE were studied to be expressed primarily in 
the liver and kidney and it mediates the exchange of tetraethylammonium 
(TEA) and 1-methyl-4-phenylpyridinium (MPP) when expressed on HEK293 
cells. MATE1 was considered an antiporter at the apical membrane of renal 
PTCs as the substrate-specificity was similar to renal and hepatic H+-coupled 
organic cation antiporters. MATE1 also transport a wide range of endogenous 
and exogenous compounds such as zwitterions (cephalexin and cephradine), 
anionic (estrone sulphate, acyclovir and ganciclovir) and cationic (TEA, MPP, 
cimetidine, metformin) compounds (93). Sato et al double-transfected MDCK 
cells to express both the MATE1 and OCT1 (MDCK-OCT1/MATE1) and 
MATE1 and OCT2 (MDCK-OCT2/MATE1) to study the transcellular 
transport of substrates by both basolateral and apical membrane transporters. 
TEA which is a common substrate for both OCT1 and MATE1 was used and 
was observed that it was transported unidirectionally from the basolateral to 
apical side in these double transfectants (46). The MATE1 dysfunctions were 
studied to have adverse effects of the drugs. Using a SLC47A1 knockout mice 
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model, increased metformin concentrations were noted in the liver leading to 
lactic acidosis was observed in knockout mice but not in the wild-type mice. 
This suggests that homozygous MATE1 variant could be one of the risk 
factors for metformin-induced lactic acidosis (94). 
1.2.3.7. P-glycoprotein (PGP) 
P-glycoprotein, one of the ABC superfamily transporters was one of the first 
members to be studied. PGP struck intense interest in researchers due to its 
overexpression linked to multidrug resistance properties. Early studies showed 
that PGP protein level was low in most tissues but higher amounts at the apical 
surface of epithelial cells at colon, brush border membrane of small intestine, 
pancreas, biliary canalicular membrane of hepatocytes, endothelial cells at the 
BBB and kidney PTCs (95). These tissue localizations suggested PGP plays a 
role in the protection of organs from toxic xenobiotics and metabolites. PGP 
has broad substrate specificity for structurally divergent compounds. The 
substrates are generally hydrophobic and some are cationic compounds. Some 
examples of PGP substrates are natural products, anticancer drugs, steroids, 
fluorescent dyes, linear and cyclic peptide and ionophores (96). As PGP 
mediates the transport of drugs used in treatment of disease, it consequently 
participates in drug absorption and disposition in vivo, eventually engaging in 
the determination of the pharmacokinetic profile of many drugs (97). It was 
studied to have an increase in 10- to 100- fold of PGP substrates in PGP 
knockout mice, suggesting that the presence of PGP prevents the accumulation 
of drugs in brains (98) (99). Many studies have been conducted to study on the 
alterations of PGP expression levels and functions in the presence of genetic 
modifications and/or under disease states. Genetic mutations were shown to 
alter PGP’s expression and functions. For example, the C3435T variant 
reduced PGP’s expression levels, leading to increased oral absorption of 
digoxin, and higher plasma drug level (100). A separate study on the same 
C3435T variant showed that it also influenced the disposition of atorvastatin 
(101). Similarly, diseases are able to alter expression levels of PGP; mRNA 
transcripts of PGP present in placenta increased in women suffering from 
gestational diabetes (102), PGP gene expression levels too increased in livers 
of rats which were induced with diabetes via STZ (103). 
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1.2.3.8. Multidrug resistance-associated protein (MRP) 
The MRP family consists of nine proteins which majority were studied to 
function as cellular resistance factors for a range of anticancer drugs. They are 
considered the “large” members because an additional (third) membrane 
spanning domain is included in their typical ABC transporter structure. 
However, this third domain function was not clearly defined (104). MRP2 was 
first cloned from hepatocytes in 1996 (105).  MRP2 is expressed on the 
important sites of absorption and elimination, such as gut epithelial cells, liver 
canalicular membranes, kidney PTCs and placental syncytiotrophoblast cells. 
The MRP2’s localisation sites also suggest roles in hepatobiliary and urinary 
elimination, as well as a barrier to uptake from the gut (104). These roles were 
further supported via the usage of MRP2 knockout mice and observations of 
increased levels of serum, urine bilirubin glucuronide, and increased 
hepatocyte glutathione levels, and decreased biliary glucuronide into bile, 
leading to increased bilirubin glucuronide transport across the hepatocyte 
membrane (106). Apart from biliary glucuronide, MRP2 transports different 
classes of compounds, such as endogenous compounds, drugs and toxic 
chemicals (107). Dubin-Johnson Syndrome caused by hereditary deficiency of 
MRP2 had emphasised on the importance of MRP2 functions in the 
hepatobiliary elimination of organic anions. Various knockout mice models 
demonstrated the important roles MRP2 play physiologically as well (104).  
Similar to MRP2, MRP3 is able to transport glucuronide, glutathione 
conjugates, and anionic bile acids and is localised in a variety of tissues 
including liver, gut, pancreas and adrenals. MRP3 protein levels were shown 
to be increased by Dubin-Johnson Syndrome and diseases like obstructive 
cholestasis, and icteric primary biliary cirrhosis. The alterations in the 
expression levels may lead to dysfunction or impaired functional effects of 
MRP3 (108). 
1.2.3.9. Breast cancer resistance protein (BCRP) 
Unlike the rest of the ABC superfamily members, which are organized in two 
TMDs and NBDs, BCRP has only half of the building blocks (i.e. one TMD 
and one NBD). Further in vivo studies on insects and bacteria suggested that 
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BCRP works as a homodimer as no other mammalian partner is required for 
BCRP to function (109). BCRP was originally cloned from drug-resistant 
cancer cells, therefore chemotherapeutic compounds were the first to be 
labelled BCRP’s substrates. One of the widely used substrates to study 
BCRP’s functions and roles is mitoxantrone. It was later discovered that 
BCRP also mediates the transport of a wide range of substrates similar to 
PGP’s. Apart from having high expression levels in resistance cancer cell 
lines, BCRP is also expressed in high levels in placenta, while lower 
expression levels were seen in brain, prostate, small intestine, testis, ovary, 
colon, liver and minute levels were detected in tissues from heart, lungs, 
skeletal muscle and kidneys. BCRP’s localisations and expression levels may 
suggest its roles in protecting stem cells, formation in the maternal-fetal 
barrier, blood-testis cell barrier and BBB; roles in absorption and efflux of 
xenobiotics and metabolic wastes in the GI tract (110). Several studies were 
carried out to investigate the role BCRP plays in the placenta in limiting fetal 
exposure of exogenous drugs and xenobiotics. Knockout mice showed 
increased topotecan, phytoestrogens, glyburide concentrations compared to 
their wildtype counterparts (111) (112). As its name suggests, levels of BCRP 
were high in cancerous cells, given that it was cloned from drug-resistant 
cancer cells. BCRP expression levels were not only influenced by diseases but 
also pregnancies. It was found that the level of BCRP in placenta was lower in 





1.2.4. Pathophysiological Changes in kidneys during diabetes 
Glomerular pathological changes such as glomerular hypertrophy, thickening 
of glomerular basement membrane and mesangial expansion and changes in 
mesangial cellularity leading to glomerulosclerosis are indicators of renal 
damage in diabetes. Apart from glomerular changes in early diabetic 
nephropathy, studies had also shown occurrence of tubular basement 
membrane expansion, tubular atrophy, interstitial fibrosis and arteriosclerosis 
as well. Therefore, diabetic nephropathy should be viewed as a disease 
affecting the entire nephron, and not solely on glomerulus.  
As early as three decades ago, observations showed renal functions were better 
correlated with tubulointerstitial changes than with glomerular changes (114). 
Subsequent findings showed transient tubular proteinuria in children suffering 
from diabetes prior to onset of microalbuminuria (115). This may encourage 
the possibility of tubular damages occurring during early stages of diabetes. 
Renal PTCs are susceptive to a range of metabolic and haemodynamic factors 
particularly diabetes associated with hyperglycaemia. Moreover, renal PTCs 
respond differently to changes such as tubular hypertrophy, tubular atrophy 
and reduced organic ion transport. However, these damages and changes in 
renal PTCs do not indicate that glomerular damages do not contribute to 
progressive diabetes. Instead, understanding the interplay between glomerulus, 
tubules and interstitum will provide researchers and clinicians better insights 
in diabetic nephropathy (116). 
A progressive research in aspects of changes in tubulointerstitium during a 
diseased state may offer further insights into the pathogenesis of diabetic 
nephropathy and improved therapeutic intervention (117). The next chapter 




1.2.5. Mechanisms leading to renal tubular injury during diabetes 
1.2.5.1. Renal enlargement 
The enlargement of kidney during early stage of diabetes was observed more 
than a century ago (118). The study concluded a 37% increase in proximal 
tubular length, doubling of wall volume and luminal diameter and increase in 
cell height during onset of diabetic nephropathy (119). As glomeruli account 
for less than 10% of kidney mass, the PTCs naturally account for the greatest 
share of kidney growth during diabetes (117). Subsequent observations 
suggested good glycemic management improved glomerular hyperfiltration 
but not nephromegaly in patients with type 1 diabetes (120). However, 
consistent glycaemic control with insulin treatment led to partial reduction in 
kidney size in diabetic patients. These reports suggested nephromegaly as an 
early indicator for nephropathy may not be definitive but it is worthy to 
conduct further research on tubular components as they make up majority of 
renal mass.  
In animal studies, an overexpression of the transforming growth factor beta 
(TGF-β) which was predominantly expressed on renal PTCs of diabetic rats 
via immunostaining was observed during early stage of diabetes (121). 
Briefly, TGF-β participates in cell proliferation and cellular differentiation in 
most cells. It was later demonstrated that neutralizing anti-TGF-β improved 
both renal hypertrophy and overexpression of matrix protein mRNA in kidney 
cortex, particularly renal PTCs (122). These observations suggested TGF-β 
could be a crucial growth factor present in renal PTCs which are capable of 
inducing tubulointerstitial fibrosis at later stages of diabetes (123). 
Furthermore, basement membrane type collagen IV which serves as a part of 
filtration system in the glomeruli of nephron had gene expression noticed four 
weeks after induction of experimental diabetes but glomerular changes were 
not consistent (124). 
1.2.5.2. Proteinuria 
Due to diabetic nephropathy, the glomerular permeability was compromised 
leading to the increased filtered plasma protein levels to renal PTCs. Such 
filtered proteins include toxins such as albumin, IgG, transferrin, lipoproteins, 
and complement components Albumin is the major component of total protein 
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present in urine. Studies have shown that albumin causes pro-inflammatory 
chemokines in PTCs, including IL-8 and monocyte-chemotactic protein 1. 
Albumin-bound fatty acids are also capable of activating peroxisome 
proliferator-activated receptor-gamma, resulting apoptosis (125).  This toxic 
proteins need to be endocytosed by tubular epithelium and broken down in 
lysosomes. During massive proteinuria, the lysosomal was punctured due to 
the overload in lysosomal capacity. This rupture leads to changes in 
expression and basolateral release of potent vasoconstrictor endothelin and 
mononuclear cell chemotactic proteins (126). The alterations in the vasoactive 
and chemotactic proteins lead to ischemia, overexpression of proinflammatory 
and fibrotic cytokines and irruption of mononuclear cells (127). 
 
1.2.5.3. Hyperglycaemia 
A high level of glucose is a key determinant for the development of diabetic 
nephropathy. It causes tubular damages via a series of mechanisms - (1) 
increase of protein kinease C which in return increases the levels of TGF-β1, 
fibronectin, and collagen type IV, (2) formation of high levels of advanced 
glycosylation end-products (AGEs), (3) increased angiotensin II synthesis 
leading to increased levels in TGF-β [18] and (4) Intensifying the sensitivity 
of tubular cells to growth promoters (128-130). 
An early study had found that excess glucose in glomerular filtrate in high 
glucose conditions (i.e. diabetes) caused a higher proximal tubular glucose 
reabsorption which deteriorated the effect of hyperglycaemia on intracellular 
glucose influx to renal renal PTCs  (131).  A more recent research showed 
elevated expression levels of collagen types I and IV in cultured PTCs 
exposed to high glucose concentrations (132). These studies showed the 
effects of high levels of glucose on renal PTCs. 
1.2.5.4. Advanced glycation-end products (AGE) formation 
The AGEs are the result of a chain of chemical reactions after an initial 
glycation reaction. The AGEs was formed via endogenous metabolism and 
aging. It was studied that AGEs formation was stimulated by both 
hyperglycaemia and oxidative stress. AGEs were then absorbed by renal PTCs 
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after being filtered by glomerulus. The ability of AGEs to activate NF-κB 
which control genes in inflammation supported the evidence that AGEs play a 
role in inflammatory of tubular compartments (133).  An in vitro study 
observed the AGEs stimulated a series of intracellular secondary messengers, 
which leads to up regulation of TGF-β in a renal tubular cell line (134). It was 
also demonstrated that not only tubular membrane basement but also renal 
PTCs  showed presence of the AGEs during diabetic condition (135). It was 
then further observed that renal PTCs  are also a site for catabolism of 
increased circulating AGEs products in diabetes (136). The binding of AGEs 
to PTCs in diabetic conditions was supported in subsequent studies. The 
adhering of AGEs products to renal PTCs  is self-regulated and dosing with 
aminoguanidine, an investigational drug for diabetic nephropathy showed 
significance in AGEs binding reduction during diabetes (137). These 
evidences support the effects of AGEs have on renal PTCs during diabetes. 
1.2.5.5. Polyol pathway 
Polyol pathway, also known as sorbitol-aldose reductase pathway was studied 
to be involved in diabetic complications, in particular retinopathy and 
nephropathy (138). Increased sorbitol concentrations were measured when 
cultured PTCs were exposed to high levels of glucose medium (139). This 
elevated amount of sorbitol was caused by the glucose metabolism. Sorbitol 
build up eventually caused the reduction of free myoinositol, deprivation of 
Na+, K+-ATPase activity, and increased disintegration of important enzyme 
cofactors of NADPH and NAD+, leading to cellular redox potential alterations 
and cellular dysfunction. In return of reduction of cofactors, the synthesis of 
glutathione, nitric oxide, myo-inositol, and taurine were reduced (140). These 
in vitro studies demonstrated the effects of high glucose levels on metabolic 
pathways, leading to deleterious effects on cellular levels.  
1.2.5.6. Vasoactive hormones 
Under high glucose condition, it was observed that interplay exists between 
angiotensin II, glucose and epidermal growth factor (EGF) induced 
hypertrophy in cultured PTCs (141, 142). A combination of glucose and 
angiotensin II enhanced TGF-β1 expression in various cells, particularly PTCs 
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and also provoked the expression of angiotensinogen which deteriorated the 
effects of long-term hyperglycaemia on proximal tubular cytokine production 
leading to oxidant stress and exaggerated extracellular matrix aggregation 
(143). Endothelin, a vasoconstrictor had an increased expression levels in the 
glomerulus and whole kidney extracts from diabetic rats (144).  However, 
endothelin overexpression situation was improved with endothelin receptor 




Ischemia during diabetic nephropathy can arise due to a series of events. The 
tubules which were able to outlive the damages caused by hyperglycaemia had 
to suffer the escalated metabolic demands, the aftermath of reduced 
peritubular flow due to postglomerular vasoconstriction, glomerular 
nonperfusion or capillary annihilation caused by tubulointerstitial expansion 
(146). The S3 segment of renal PTCs  was discovered to be exceptionally 
susceptible to kidney and ischemic injury due to the accumulative tubular 
concentration, interstitial hypertonicity, and low oxygen strain in this certain 
region of renal PTCs   (147).  Subsequent research had conformed the above 
as collagen overexpression occurred largely at the S3 segment and TGF-β 
biological activity in the diabetic rat is located primarily at S3 segment of 
renal PTCs (148, 149). Patients with initial diabetic nephropathy showed a 
correlation between glycated hemoglobin and urinary excretion of intestinal 




1.3. Animal models for diabetes 
As complex interactions between genetics and environment factors contribute 
to the development of diabetes, these lead to the genetic analyses of diabetes 
in human difficult and inadequately understood (151). Furthermore, diabetes 
research in humans is often hindered by ethical considerations. Animal models 
of diabetes are therefore useful as they are able to offer new insights into 
human diabetes. While several successful models have been developed in 
larger animals (primates and pigs), they are less frequently used due to their 
sizes and higher cost (152, 153). On the other hand, small animals like rodents 
are commonly used due to their ease of handling and economic factor.  
Such diabetic rodent models are categorized into two groups – genetically 
induced spontaneous diabetic models and experimentally induced non-
spontaneous diabetic models.  
1.3.1. Genetically-induced spontaneous diabetic rat models 
There are the Zucker diabetic fatty (ZDF), Ostuka Long Evans Tokushima 
Fatty (OLETF), Goto Kakizaki (GK), spontaneously diabetic Tori (SDT) rats 
and genetically developed db/db+/+ mice under the genetically induced 
spontaneous diabetic models category. Although these models are capable of 
developing spontaneous diabetes, insulin resistance and reduced β-cell mass, 
they require high maintenance fees, generally more expensive; mortality rate 
is higher due to ketosis in case of animals with brittle pancreas and not as 
easily accessible for research experiments (154). 
1.3.2. Experimentally-Induced Type 2 Diabetes Rodent Models 
Experimentally-induced diabetic rodent model uses rodent strains which are 
not diabetic under normal conditions. Diabetes is induced via a variety of 
methods. Compared to their genetically engineered counterparts, this model is 
cheaper; strains are more readily available and operationally straight forward. 
Moreover, they are susceptible to diabetic induction by chemicals (alloxan, 
STZ or nicotinamide), partial pancreatectomy, undergoing long term high-fat 
diets, monosodium glutamate (MSG) or combinations of these. Such rodent 
model develops most T2D biochemical and pathology symptoms which 
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resemble humans. However, there is no single rodent model which represents 
human T2D currently. Therefore, researchers had developed several selective 
models for diabetes-related complications for further studies in diabetes. 
1.3.2.1. Alloxan or STZ (STZ) rodent model 
1.3.2.1.1. Adult model 
Alloxan (a uric acid derivative) and STZ (product of Streptomyces 
achromogenes) act by destroying pancreatic beta cells specifically by 
oxidative stress induction, causing insulin deficiency, hyperglycaemia and 
ketosis (155, 156). In the 70s, such chemicals were used to induce diabetes in 
animal rodents, but it resembles T1D known today (157, 158). After World 
Health Organization's classification of T1D and T2D in 1980, further 
modifications had been made to existing protocols to mimic characteristics 
observed in human T2D (159, 160). Ito et al was the first group to develop a 
T2D rodent model by injecting 100mg/kg STZ into 8-week-old mice (161). 
This particular model developed progressively increasing hyperglycaemia, 
increased food and water consumption, glucose intolerance and insulin 
resistance which differed from age-matched controls after 9 weeks (162). 
Although the above models were relatively straightforward a long time is 
required for the induction of diabetes.  
1.3.2.1.2. Neonatal model 
Bonner-Weir et. al developed a T2D rodent model using neonatal rats (2-day-
old) in 1981 (163). Subsequent studies adopted the similar approach and 
developed a T2D neonatal rodent model with hyperglycaemia, with the 
reduction of beta cells and insulin resistance in both male and female neonatal 
rats (164, 165). A range of STZ dosage (25mg/kg to 80mg/kg) had been 
experimented on neonatal male spontaneously hypertensive rats (SHR). The 
rats developed mild to moderate hyperglycaemia, increased glycated 
haemoglobin, increased urinary glucose excretion and increased food intake 
after the administration of lower doses of STZ at 25mg/kg and 37.5mg/kg. At 
higher doses (50, 62.5, 70mg/kg), neonatal rats developed frank 
hyperglycaemia, body weight reduction which resembled T1D instead of T2D 
(166). 1.5-day-old neonatal male and female Fischer 344 rats were injected 
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with 80mg/kg STZ and it was recorded that this particular model resulted in a 
diabetic state without affecting the growth and function of thyroid in 
adulthood and also displayed obvious characteristics of TD2 which are mild 
hyperglycaemia, minimal change in insulin levels, slight increase in glucagon 
levels and no change in ketones level (167). Two-day-old Wistar rat were 
induced with diabetes by injection of 90mg/kg STZ and fasting 
hyperglycaemia, glucose intolerance, insulin resistance and elevated liver 
enzymes which are characteristics of T2D were observed after 12 weeks (168). 
Compared to the adult rat models, neonatal model seems to be a better option 
as the models display more typical T2D characteristics. However, there are 
variations in sensitivity to chemical inducers in different species of neonatal 
rats. Therefore, it is important for researchers to conduct validation studies 
using antidiabetic drugs when adopting such models. Furthermore, due to the 
nature of newborns, it requires more attention and effort in handling, 
especially during administration of chemicals via intravenous and 
intraperitoneal routes.  
1.3.2.2. Nicotinamide (NCT) and/or STZ rodent model 
Nicotinamide is known to be an antidiabetic drug but when used in low 
concentrations together with STZ, it is able to induce diabetes with 
pathogenesis of T2D. In 1998, a cocktail of NCT and STZ was injected into 3-
month-old Wistar rats. This model displayed stable non-fasting 
hyperglycaemia and glucose intolerance (169). Nakamura et al demonstrated a 
T2D non-obese mice model using a combination of NCT and STZ. The model 
had developed a T2D profile with increased body weights, glucose intolerance 
and insulin resistance. It took six weeks for the diabetes to set in, which is a 
relatively short period of time required. Researchers are able to induce an 
obese model with the addition of high fat diet into similar protocol (170). 
1.3.2.3. Partial pancreatectomy model 
A range of partial pancreatectomy models had been studied thus far. A partial 
pancreatectomy model (60%) was developed using CD rats. Although rats 
developed hyperglycaemia, reductions in beta cell mass, pancreatic weight, 
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insulin content and insulin response, no change was observed in insulin levels 
(171). However, male SD rats which underwent 85% to 95% pancreatectomy 
had developed stable hyperglycaemia and reduction in insulin secretion for 
three weeks (172). Partial pancreatectomy (50%) was later combined with 
high doses of NCT and STZ to remove and destroy sufficient beta cell mass to 
induce diabetes and lower the chances of mortality. Drastic loss in body 
weight, decreased serum and pancreatic insulin levels and low levels of stable 
hyperglycaemia were then observed using such model (173). A study which 
involved a 50% partial removal of pancreas showed an improvement in 
glycaemic levels as soon as eighth day of post-operation and remained 
normoglycaemia throughout the 13 weeks period. Furthermore, mortality rate 
was high (70%) due to hyperglycaemia in diabetic, sham-operated animals 
(174). Although partial pancreatectomy was one of the earliest methods used 
to induce diabetes in animals, a major limitation is the regeneration of 
pancreatic islets and the high mortality rate.  
1.3.2.4. Monosodium glutamate (MSG) model 
MSG is commonly used as a taste enhancer but numerous studies showed its 
ability to induce diabetes in rodents. In a 1998 study, T2D-related 
characteristics (obesity, impaired glucose tolerance, hyperinsulinemia and 
hypertriglyceridemia) were observed in neonatal SHR rats after injection of 
MSG for 5 days (175). Miyamoto et. al later developed a MSG-induced T2D 
model using neonatal male and female ICR mice. MSG (2mg/g) was 
administered to mice daily for 5 days from birth. It was then observed that the 
mice developed hyperglycaemia, increased serum insulin, abnormal lipid 
profiles, glucose intolerance, insulin resistance and abnormal liver function in 
the male mice within 10 weeks of study. This condition was sustained for the 
entire year of experimental period. Although diabetes was induced within a 
relatively short period of time, the diabetic mice later developed liver tumours 
which may be a confounder when interpreting pathogenesis of T2D in this 
MSG model (176). 
1.3.2.5. Long-term high-fat diet (HFD) model 
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After World Health Organization’s categorization of T1D and T2D in 1980, 
usage of high-fat diet to induce diabetes with insulin resistance and obesity 
became very popular among researchers. Several groups of researchers used a 
varying degree of fat contents or fat sources to induce diabetes. Following the 
introduction of high-fat diet (58% lard) to C57BL/6J mice for ten weeks, 
higher levels of food intake, body weight and blood glucose levels were 
remarkably noticeable when compared to mice which underwent low-fat diet 
(11% lard) (177). However, certain strains of rodents appeared to be more 
susceptible to effects of high-fat diet. In a separate study which involved 
feeding three different strains of male mice (JF1, C57BL/5J and MSM) with 
30% lard over ten weeks, it was observed each strain displayed different 
characteristics. Both JF1 and C57BL/5J mice showed higher blood glucose, 
serum insulin, insulin resistance and leptin levels compared to MSM mice 
(178). 
It was studied that rats required a longer period of HFD intake for the onset of 
diabetes. Male Wistar rats were fed with 65% fat diet (from vegetable sources) 
for 16 months and they developed progressive impaired glucose tolerance, 
reduced insulin secretion and insulin resistance. However, there was only a 
mild increase in fasting glucose level in high-fat diet group compared to 
regular chow group (179). In 2004, Huang et al managed to induce diabetes in 
SD rats by feeding them with animal-derived high-fat diet (20% lard) for eight 
weeks. The SD rats developed hyperglycaemia, increased body weights and 
increased glucose intolerance than controls which were fed regular chow 
(180). Although the effects of long term high-fat diet were similar to 
conditions associated to T2D induced in humans, the time required to develop 
this model is a limiting factor. Furthermore, researchers had to take note of 
species used as previous studies had shown susceptibility to diabetes in 
specific strains (178).   
1.3.2.6. High-fat diet and STZ rodent model (HFD-STZ) 
As more diabetic rodent models were being researched on and developed, 
better understanding of such was applied on the combination of chemical 
inducers and high fat diet to develop a model which mimic human T2D 
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pathogenesis. Among all, Reed et al were the first to develop a diabetic rodent 
model by feeding male SD rats with a diet of 40% calories from animal fats 
for two weeks before administration of STZ (50mg/kg). Blood tests showed an 
increase in plasma glucose within 3 days after STZ injection and 
hyperglycaemia lasted till end of study (21 days). This particular diabetic 
rodent model had increased body weight (not obesity), increased fasting blood 
glucose levels, serum insulin, free fatty acids, and triglycerides (181). 
Adopting this model, Zhang et al developed a diabetic SD male rat model 
from a combination of HFD (30% zoosterol) and a lower dose of STZ 
(15mg/kg). Similarly, increased levels of fasting blood glucose, serum insulin 
and triglycerides were observed and the diabetic state could sustain for the 16 
weeks study. However, compared to the previous animal model, Zhang’s 
model required two months to develop diabetes as a lower dose of STZ was 
used (182). In 2005, Srinivasan et al. fed a HFD (58% from lard) for two 
weeks before injection of varying doses of STZ (25, 35, 45 or 55mg/kg) to 
male SD rats. It was observed that 25mg/kg STZ did not induce significant 
hyperglycaemia in both regular diet and HFD groups, and thus the study did 
not proceed further. As for rats injected with 45 or 55mg/kg STZ, frank 
hyperglycaemia was induced in both regular diet and HFD groups. 
Furthermore, there was drastic weight reduction and some rats died within two 
weeks of STZ administration. Glipizide and Pioglitazone which are 
antidiabetic drugs were unable to change the plasma glucose levels of these 
diabetic rats. Thus, these fat-fed rodents resembled more of T1D rather than 
T2D. As for 35mg/kg, frank hyperglycaemia and increased body weight were 
induced in HFD rats and not seen in regular diet group after 7 days of STZ 
administration. Therefore, Srinivasan et al chose the combination of HFD with 
single dose of 35mg/kg STZ generate a T2D rat model for further studies 
(154). Subsequently, Danda et al adopted similar combination (HFD and 
single dose 35mg/kg STZ) to induce a T2D rat model (183). The above studies 
showed HFD STZ rat models were able to develop T2D pathogenesis similar 
to human T2D within a relative short period. However, researchers must take 




1.4. Animal models for diabetic nephropathy 
 
Kidney disease which is characterised by proteinuria and glomerular lesions is 
one of the many complications of diabetes mellitus. While spontaneously 
diabetic animal models displayed typical hallmarks of nephropathy such as 
mesangial expansion and glomerular basement membrane thickening as seen 
in human diabetic nephropathy, there is currently no single animal model that 
can develop renal changes identical to those seen in humans. Therefore, 
animal models are being developed to better understand the disease 
pathogenesis and develop drugs for nephropathy. This chapter will review on 
the various rat models used in the study of diabetic nephropathy.  
 
1.4.1. Animal models of spontaneous diabetic kidney disease 
 
GK rats are a genetically engineered breed of a non-obese model of type 2 
diabetes mellitus. While hyperglycaemia was noted in GK rats from the age of 
8-months-old and they later developed nephropathy by 24 months of age via 
the observations in increased in serum creatinine, blood urea nitrogen, 
glomerulosclerosis and tubulointerstitium fibrosis (184, 185). Such renal 
changes seen in GK rats are similar to those of progressive human diabetic 
nephropathy (184, 185). Similarly, CD1 mouse model had been used for the 
development of end-stage renal disease which is distinguished by prominent 
tubulointerstitium fibrosis and glomerulosclerosis within 6 months after a 
single injection of STZ. These mice later on developed increase serum 
creatinine and proteinuria, mesangial matrix expansion and glomerular 
hypertrophy (186). 
 
1.4.2. Experimental models to induce diabetic nephropathy 
As explained previously, STZ is commonly used to destroy the beta cells of 
Islets of Langerhans in the pancreas to induce experimental diabetes. It was 
studied that rats which received the combination of removal of 1.5 kidneys 
and single low dose STZ produced macroalbuminuria, increased serum 
creatinine and triglycerides with both glomerular and tubular lesions in less 
than 12 weeks (187). Danda et al managed to induce diabetic nephropathy into 
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rats using a combination of HFD and single dose STZ within 6 weeks after 
STZ injection. Hyperglycaemia, abnormal proteinuria, and factors such as 
hypertension, hypercholesterolemia, and/or hyperinsulinemia contributed to 
the formation of glomerular lesions (183). It was later studied that 
hyperglycaemia was induced within 72 hours after a single dose of STZ was 
administrated into rats (188). Signs of nephropathy such as increased 
proteinuria, serum creatinine, blood urea nitrogen, extracellular matrix 
deposition and glomerular basement membrane thickening were noted 
between 4 to 8 weeks after the initial STZ administration (188). Mice which 
received dual 125mg/kg/day STZ administration demonstrated nephropathy, 
characterised by the accumulation of macrophages, increased proteinuria, 





1.5. Applications and techniques used 
 
1.5.1. Laser Capture Microdissection 
Gene expression studies of isolated tissues are often confounded by the reality 
that such tissues are highly heterogeneous. Scientists had been consistently 
researching on various methods to isolate pure cell populations. Almost three 
decades ago, a method based on hypotonic lysis, Ca2+ aggregation of 
contaminants and differential centrifugation was developed for isolation of 
pure renal renal PTCs  (190). Ten years later in 1989, a strategy for rat renal 
PTCs collection utilizing dissecting forceps and dish with direct was 
developed (191). Toutain et. al. subsequently isolated rabbit renal PTCs via 
multiple sieving. Briefly, glomerulus was removed using immunomagentic 
separation. The final PTCs suspension was viewed under a transmission 
electron microscope for confirmation purpose (192). Subsequent modifications 
were made to existing protocols to maximize the number of cells. PTCs were 
either sorted through multiple sieving, immunomagnetic binding or grown in 
primary culture (193, 194). The difficulty in obtaining a pure cell population 
had often imposed a huge challenge for researchers. Very often, manual 
isolation of cells is laborious, requires long working hours and complicated 
procedures. Further culturing of cells may also alter cells' biochemical and 
morphological characteristics (193). Although manual dissection offers good 
precision, this method requires high degree of technical expertise. 
Furthermore, the above mentioned methods did not provide the efficiency 
required for routine research or clinical diagnostic applications (195). 
Lance A. Liott and team had successfully developed a method known as laser 
capture microdissection (LCM) which allows researchers an efficient and 
straightforward protocol to achieve pure cell populations within a short period 
of time (195). The LCM methodology is illustrated in Figure 1.4. A LCM 
system has a laser coupled to microscope and allows magnified visualization 
of histological samples. It requires a cap coated with an adhesive, transport 
film to be placed over a tissue section. Using the heat from short-duration, 
focused pulse from infra-red laser, cells of interest can be selected and be 
transferred to the cap with adhesive film. The film with procured tissue is then 
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removed from the section and placed directly into DNA, RNA, or enzyme 
buffer for downstream processing.   
 
Figure 1.4 - Illustration of LCM methodology. LCM requires a thin 
transparent film adhered to a cap to be placed over a tissue section, visualizing 
the tissue microscopically, and selectively adhering the cells of interest to the 
film with a fixed-position, short-duration, focused pulse from an infra-red 
laser. The film with procured tissue is then removed from the section and 
placed directly into DNA, RNA or enzyme buffer for later processing (196).  
 
As compared to preceding cell isolation methods, LCM is straightforward with 
a mere one-step transfer, requires no moving parts, no manual microdissection 
or manipulations. Moreover, the transferred cells of interest are able to retain 
original morphologies, thus allowing microscopic verification of the 
specificity of captured material. Potential contamination which interferes with 
PCR-based analyses is eliminated with the use of sterile, disposable transfer 
films. LCM has no restriction on the type of tissue samples to be processed; 
samples which are frozen, paraffin-embedded, formalin or alcohol-fixed 
tissues, histological-stained or unstained tissues are all suitable for LCM 
application (195). With such advantages, renal PTCs from rodents and humans 
were successfully isolated for numerous gene expression studies (197-200). 
These techniques have been applied on the studies of other disease states such 
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as breast cancer and colon cancer (201, 202). LCM application equipped with 
molecular and proteomic approaches provides researchers a better 





1.5.2. Quantitative Real-Time Polymerase Chain Reaction (qPCR) 
qPCR has been incorporated into studies looking into gene expression, copy 
number determination, gene or cell therapy biodistribution and pathogen 
detection. Such studies allow the advancements of discovery and marketing of 
novel therapeutics and biopharmaceutical products (203). 
Contrary to endpoint PCR, qPCR measures the fluorescence at each cycle as 
the PCR amplification progresses. The quantitation of template is based on the 
fluorescent signal during the exponential phase when limiting reagents, 
accumulation of inhibitors, or inactivation of polymerase have started to have 
an effect on the efficiency of amplification. A fluorescent reporter molecule is 
used to monitor the progress of amplification reaction. In some platforms, this 
graphic display can be truly observed in real time, whereas in some 
instruments, the time course of product amplification is obtained after 
completion of the whole reaction using information obtained during each PCR 
cycle (204). During the early stages of PCR, the level of fluorescence is 
almost equivalent to background noise. The fluorescence then moves to an 
exponential, linear and eventually plateau phase. For the qPCR analysis, a 
predetermined threshold is set above a threshold limit. An interpolated cycle at 
which the fluorescence time course reaches the threshold is determined. This 
value is also known as threshold cycle (Ct) and is the unit for qPCR. Ct value 
is related to the expression levels of target genes. A low Ct relates to a higher 
expression levels due to a higher starting copy number and vice versa (205). 
There are both direct and indirect methods for the generation of fluorescence 
during PCR reaction. Indirect method utilises a system that yields fluorescence 
generated during the primer extension step of amplification. Thus includes the 
Taqman system which uses the intrinsic 5’ nuclease activity of Taq 
polymerase to digest a probe that has annealed to the gene of interest. This 
probe contains a quencher and reporter fluorochromes separated by a specific 
DNA or cDNA sequence. The proximity of the quencher to the reporter on the 
intact probe quenches that fluorescence of the reporter fluorochrome. Taq 
DNA polymerase-associated 5’ nuclease digestion of the probe leads to 
degradation of probe and separation of fluorochromes. This loss of quenching 
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will result in amplification-associated production of fluorescence. As for direct 
methods, systems utilise the binding of a fluorescence molecule or compound 
to the amplified PCR product or a direct addition of a fluorescence 
interference probe into the PCR product. There are a few direct assays such as 
molecular beacons and SYBR Green. Molecular beacons are hairpin probes 
which uses fluorescence interference. The hairpin keeps the fluorochrome in 
sight to allow quenching of the fluorescence of reporter, following binding and 
disruption of the hairpin being used to alleviate the fluorescence quenching. 
Another straightforward direct method is the involvement of SYBR Green, a 
fluorescent dye which binds to double-stranded DNA (204). 
Absolute or relative quantitations are two commonly used methods for 
presenting qPCR data. Absolute quantitation is usually applied when a precise 
quantity of amplicon is required, for instance, calculation of viral load. This 
particular method generates the exact copy number following transforming of 
the qPCR through a standard curve (205). 
Relative quantitation is a relatively easier and straightforward analysis method 
compared to absolute quantitation. There are a few methods of analyses for 
relative quantitation. The sigmoidal curve fitting method fits the experimental 
data to an empirical equation and results in the prediction of PCR efficiency 
and estimation of initial copy number of amplicon. Another popular method is 
known as the comparative Ct method (2-∆∆Ct). This method assumes the PCR 
efficiency of target gene is similar to internal control gene for comparison. 
The advantage of 2-∆∆Ct method is the ease of use and the ability to present 
qPCR data as ‘fold change or regulation’ in terms of expression levels. 
However, users need to ensure that “assumptions of similar PCR efficiencies” 
are valid (205). 
One of the challenges in qPCR is the acquiring of good quality RNA. RNA is 
very unstable after isolation and can degrade via cleavage by RNases which 
can be found in tissues where RNA originates, working environments and/or 
reagents used for isolation (206). Therefore, ensuring good RNA quality is the 
first important step in achieving meaningful qPCR data. 
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Total RNA is often assessed via 260/280 and 260/230 ratios to test for protein 
and organic compounds contaminations respectively. However, such 
measurements do not generate results with regards to RNA integrity. In the 
past, tedious denaturing agarose gel with ethidium bromide was utilised to 
assess RNA intactness but it requires the use of high RNA concentrations to 
be utilised. Therefore, such method is not ideal for scarce samples, for 
example microdissected samples where only minute concentration is achieved. 
A new and advanced tool for RNA integrity assessment is the RNA Integrity 
Number (RIN) which was developed by Agilent Technologies. This method 
assigns a RIN number score from 1 to 10, where 10 represents a completely 
intact RNA and 1 represents a highly degraded RNA. Similar to the denaturing 
agarose gel used in the past, this lab-on-chip technology also allow the 
visualization of the 18S and 28S ribosomal RNA bands which symbolise RNA 
intactness. 
Fleige and Pfaffl demonstrated the dependence of RNA integrity on different 
RNA sources (calf tissues, white blood cells and four different cell lines). It 
was shown that RNA isolated from solid tissues generated a range of RIN 
between 6 and 8. This may be due to the high levels of connecting tissues 
present in tissues or organs, therefore contains a higher RNA enzymatic 
activity. Furthermore, additional steps are required for tissue sampling and 
storage during RNA isolation from tissues or organs. On the other hand, cells 
(white blood cells or from cell lines) had a better (higher) RIN. This 
observation can be explained by the fact that cell sampling and RNA 
extraction is more straightforward and faster compared to extraction from 
whole tissues. These findings act as a reminder for interested researchers to 
take note of prospective sample origins which may interfere with RNA quality 
(207). 
Several researchers then studied the effects of RIN had on qPCR data. Huch et 
al performed qPCR with a gradient of intact RNA (RIN 8 to 10) down to 
degraded RNA (RIN 1 to 3). They then correlated the RIN values with Ct of 
qPCR. It was observed that the high-quality RNA (higher RIN) generated a 
lower Ct when compared to the degraded RNA (lower RIN). Furthermore, the 
better RNA integrity was the variability of qPCR results reduced (208). A 
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subsequent research strongly recommend that RNA quality control be 
performed before qPCR assays and suggest RNA samples of high quality 
(RIN 8 and above) as template for qPCR. This was based on the reasoning that 
partially degraded RNA (RIN 6 to 8) will result in sub-optimal qPCR data and 
degraded (RIN 5 and below will interfere with qPCR performance as PCR 
efficiencies were observed to be affected by both tissue type and RNA 
isolation methodologies (207). 
Although there is no statistically confirmed studies at which RIN will be a cut-
off to deem unsuitable for qPCR, it is highly recommended for researchers to 
perform such RNA quality checks to ensure proper quality assurance. In 
addition, the release of MIQE guidelines in 2009 encourages a good assay 
design and transparency of protocols, data analysis and conclusions. Since the 
release of MIQE, close to 30 papers were published in accordance to this set 
of guidelines. This further motivates researchers to input valuable qPCR 
protocols and data for a more meaningful approach for future fellow mates to 






The current study hypothesizes specific drug transporters localized on rat renal 





The aims of the study are to: - 
 Develop an optimal protocol for the isolation of good quantity and quality 
RNA for gene expression studies.  
 Investigate the combination of high fat diet and single low dose STZ for 
the induction of diabetic nephropathy. 
 Understand the changes in gene expression levels of drug transporters 




1.8. Study Design 
A total of thirty-four male 6-week-old Wistar rats were used in the study. All 
rats were allowed a week of acclimation. Six rats were randomly selected to 
form the Baseline group (n=6) and were euthanized after the acclimation 
week. The remaining 28 rats were then randomly divided into two groups to 
undergo two different treatments. Sixteen rats were fed HFD throughout the 
study and were administered with a single low dose STZ (35mg/kg) for the 
induction of diabetes after first five weeks of HFD. The remaining 12 rats 
were the age-matched controls for the diabetic rats. These control rats were 
given regular rat chow and citrate buffer injection.  At three weeks after STZ 
or citrate buffer administration, eight diabetic (forming D1 group) and six 
control rats (forming C1 group) were sacrificed while the remaining rats were 
sacrificed at 8 weeks after STZ or citrate buffer administration. Figure 1.5 
illustrates the outline of this study design.  
Non-fasting plasma glucose levels were measured at three time points - a week 
pre-STZ, a week post-STZ and upon euthanizing of animals. Total protein, 
albumin and creatinine levels were measured using urine collected for 24hours 
prior to sacrifice of animals.  
Figure 1.6 outlines the work flow in current study. Rat kidneys were collected 
after euthanizing and subjected to sample preparation for the collection of 
PTCs via LCM. Total RNA was extracted from PTCs using commercially 
available kit. The quality of total RNA was then assessed before commencing 






Figure 1.5 - Study design. A total of thirty-four male 6-week-old Wistar rats were used in the study. All rats were allowed a week of 
acclimation. Six rats were randomly selected to form the Baseline group (n=6) and were euthanized after the acclimation week. The remaining 
28 rats were then randomly divided into two groups to undergo two different treatments. Sixteen rats were fed HFD throughout the study and 
were administered with a single low dose STZ (35mg/kg) for the induction of diabetes after first five weeks of HFD. The remaining 12 rats were 
the age-matched controls for the diabetic rats. These control rats were given regular rat chow and citrate buffer injection.  At three weeks after 
STZ or citrate buffer administration, eight diabetic (forming D1 group) and six control rats (forming C1 group) were sacrificed while the 





Figure 1.6 - Outline of work flow. Rat kidneys were collected after sacrifice. 
Kidney were then sectioned and stained for the collection of renal PTCs via 
the use of laser capture microdissection. Total RNA extraction will then be 
performed using commercially available kit. Quality of total RNA will be 
assessed before applying the total RNA for gene expression studies.  
These findings will enhance our understanding on (i) how rats with diabetes 
induced by a combination of high-fat diet and single low dose STZ will 
develop diabetic nephropathy (ii) evaluate differential gene expression levels 




2. MATERIALS AND METHODS 
 
2.1. Animals 
A total of 34 6-week-old male Wistar rats were purchased from the A*Star 
Biological Resource Centre. The rats were housed in temperature controlled 
room at 25 ± 1˚C with lighting from 0700am to 1900pm daily and were 
allowed one week of acclimation before the commencement of study. The rats 
were randomized into five groups - baseline, C1, D1, C2 and D2. The use of 
animals in this study was approved by Institutional Animal Care and Use 
Committee of A*Star. The study design was elaborate in chapter 1.7.  
 
2.2. Induction of diabetes 
The control rats (C1 and C2 groups) were given regular rat chow (2918.CS; 
Harlan Teklad) while diabetic rats (D1 and D2) were given HFD (TD.03584; 
Harlan Teklad) after acclimation week. Table 2.1 shows the comparison of the 
nutrient content between regular and HFD. All animals were given free access 
to both food and water.  
Table 2.1 - Comparison between regular and HFD.   
 Regular Chow High Fat Diet 
Protein % 18 20.4 
Fat % 6 35.2 
Source of Fat Soybean Oil Lard 
 
After 5 weeks of respective diets, D1 and D2 groups were given a single dose 
of STZ (35mg/kg) intravenously. STZ was weighed and dissolved in citrate 
buffer (0.01mol/L, pH 4.5) on the day of use. C1 and C2 groups received only 
citrate buffer as vehicle. All rats were anesthetized using isofluorane 
inhalation during STZ or citrate buffer administration.  
2.3. Rat kidney collection and sectioning 
The rats were euthanized via carbon dioxide asphyxiation with the help from 
Histopathology Facility (A*star). Both kidneys were removed immediately 
after death and middle cross-section was sectioned using a sterile blade. 
Sectioned kidneys were wrapped in aluminium foils and snapped frozen in 
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liquid nitrogen immediately. Frozen kidneys were then transferred to Leica 
Cryostat (Leica Biosystems) at -16⁰C. Kidneys were embedded onto block 
holder using Tissue-Tek® OCTTM Compound (Sakura, The Netherlands). 
Kidneys were sectioned thrice with 10µm in thickness. Sections were then 
gently transferred onto PEN membrane glass slides. Slides containing sections 
were allowed to dry in cryostat for 2 minutes before Hematoxylin and Eosin 
(H&E) staining. 
2.4. Modified H&E staining 
Modified H&E staining was performed with the help from Histopathology 
Facility (A*star). All procedures were performed on wet ice to minimize 
RNase activity. Table 2.2 lists the steps in a modified H&E staining protocol 
which was able to stain renal cells in approximately five minutes. All reagents 
were freshly prepared and filtered on the day of usage. Nuclease-free water 
was used in steps which require water. Step 1 of staining (drying of slides) 
was performed in cryostat at -20°C. Steps 2 to 13 were performed on ice, in a 
fume hood.   
Table 2.2 - A modified hematoxylin and eosin staining protocol. Step 1 was 
performed in a cryostat at -20°C while remaining steps were performed in a 
fume hood, on ice. Reagents were freshly prepared and filtered on day of 
usage. Nuclease-free water was used in steps which required water. 
Step Number Reagents Time in reagent 
1 Air dry slides in cryostat for 2 minutes before 
commencement of staining in fume hood.
2 70% Ethanol 30 seconds 
3 Water 5 seconds 
4 Hematoxylin 2 10 seconds 
5 Bluing Reagent 10 seconds 
6 70% Ethanol 10 seconds 
7 Eosin/Phloxine 2 seconds 
8 100% Ethanol 5 seconds 
9 100% Ethanol 30 seconds 
10 100% Ethanol 30 seconds 
11 Xylene 5 seconds 
12 Xylene 30 seconds 
13 Xylene 1 minute 
 
2.5. Histology tissue preparation 
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Histology tissue preparation was performed with the help from Histopathology 
Facility (A*star). Rat kidney tissues were trimmed to a thickness of 
approximately 4mm with the use of a single edge trimming blade and were 
then placed into labelled cassettes. These samples were then processed using 
the Tissue-Tek® VIP 5TM tissue processor. This one hour protocol procedure is 
listed in appendices 1. Microtomy was performed using Leica RM 2255 
microtome with sections cut at 5µm thickness and placed onto labelled 
microscope slides. Slides were allowed to dry before H&E staining. H&E 
stain was performed using Leica autoStainer XL and coverslipped using the 
Leica CV 5030 auto coverslipper. The H&E stain procedures were listed in 
appendices 2.  
 
2.6. Collection of rat renal PTCs via LCM 
LCM was performed with the help from Histopathology Facility (A*star). 
Stained slides were placed on ArcturusXT™ LCM instrument (Applied 
Biosystems, USA) modular stage. Illumination contrast and desired 
magnification objective were adjusted for optimal visualisation. Using simple 
drawing tools supplied, renal PTCs or desired cells were outlined on monitor 
screen for microdissection. After dissection, renal PTCs or desired cells 
captured and transferred onto CapSure® HS LCM Caps (Invitrogen, USA) 
were inspected under microscope for reconfirmation.   
2.7. Determination of number of renal PTCs required for qPCR 
The stained slide was placed on ArcturusXT™ LCM instrument (Applied 
Biosystems, USA). A mixture of renal cells (consisting glomerulus, distal and 
proximal tubular cells) was captured onto CapSure® HS LCM Caps 
(Invitrogen, USA). 3000, 8000 and 18000 mixed renal cells were collected 
within 20 minutes. There was an attempt to collect the maximum number of 
renal cells were collected within 20 minutes and transferred to the CapSure® 
HS LCM Caps. In case of insufficient caps, multiple attempts were performed 
to collect the desired number of caps on multiple caps. Caps containing cells 
were placed on ice until desired number of cells was fully collected before 
commencing RNA extraction.  
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2.8. Modified total RNA isolation and DNase I treatment 
Total RNA was isolated immediately after microdissected renal PTCs. 
PicoPure® RNA Isolation Kit (Applied Biosystems®) was used for the total 
RNA extraction according to manufacturer’s protocol with several 
modifications.  
Briefly, microdissected PTCs on caps and ExtracSure Extraction Device was 
assembled. This assembly was placed in a HS Alignment Tray and 30µL of 
Extraction Buffer (XB) was gently pipetted into the well and the alignment 
tray was covered with a pre-warmed incubation block. The assembly was then 
incubated for 30 minutes at 42°C. Microcentrifuge tube with CapSure-
ExtracSure assembly was centrifuged at 1000g for 2 minutes for collection of 
cell lysate to the bottom of centrifuge tube. The RNA Purification Column 
was pre-conditioned by adding 250µL of Conditioning Buffer (CB) and 
incubated the column containing CB for 5 minutes at ambient temperature. 
The RNA Purification Column was then centrifuged at 16, 000g for 1 minute 
for removal of CB. Thirty microliter of 70% Ethanol was added to the cell 
extract and mixture was mixed well by pipetting up and down gently. The cell 
extract-70% Ethanol mixture was transferred to RNA Purification Column and 
centrifuged at 100g for 2 minutes for RNA binding, followed by a quick spin 
at 16, 000g for 30 seconds to remove flowthrough. This step was repeated 
twice to ensure maximal RNA binding to the column membrane. A hundred 
microliter of Washing Buffer 1 was pipetted to the same RNA Purification 
Column and centrifuged for 1 minute at 8, 000g. Bound RNA was treated with 
DNAse I (RNase-Free DNase Set, Qiagen). Ten microliter of DNAse I Stock 
Solution was added to 30µL RDD Buffer and mixed well via gently pipetting. 
Mixture was then added to RNA Purification Column containing bound total 
RNA and allowed to stand in ambient temperature for 30 minutes before 
addition of 40µL Wash Buffer 1 and centrifuged at 8, 000g for 15 seconds to 
stop the treatment. Bound RNA was washed twice with 100µL of Wash Buffer 
2. The purification column was transferred to a new 0.5mL microcentrifuge 
tube and 11µL elution buffer was added. Tube assembly incubated at room 
temperature for 1 minute and centrifuged at 1, 000g for 1 minute to distribute 
elution buffer in the column, followed by spinning at 16, 000g for 1 minute to 
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elute RNA. The eluent was then transferred back to the same purification 
column and elution was repeated twice to maximize total RNA yield.  
2.9. RNA quality control 
2.9.1. RNA integrity number (RIN) 
RIN was measured at different stages of sample preparation as shown in 
Figure 2.1 to ensure good quality RNA can be obtained. In addition, RIN was 
measured also for archived kidney tissue stored for six months in -80°C and 
PTCs collected within 40 minutes too. RIN was measured using Agilent 2100 
Bioanalyzer with Agilent RNA 6000 Pico Kit. All procedures were performed 
according to manufacturer’s protocol. Thereafter, random samples from each 
group were chosen for RIN assessment.  
 
Figure 2.1 - Progressive stages of collection of rat PTCs. It shows step-by-
step protocol to the collection of renal PTCs from whole kidney tissue.  
2.9.2. Total RNA concentration and purity ratios 
NanoDrop 2000 UV-Vis Spectrophotometer (Thermo Scientific) was used to 
assess the 260/280 and 260/230 purity ratios immediately after RNA 
extraction. Approximately 1.5µL of total RNA were used for the measurement 
of concentrations and purity ratios analysis. RNA elution buffer from PicoPure 
Total RNA isolation kit was used as blank.  
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2.10. Body weight, blood and urinary parameters 
 
2.10.1. Measurement of non-fasting plasma glucose 
Non-fasting, morning blood glucose concentrations were measured thrice 
throughout the 13-week study; a week before and after STZ injection and upon 
sacrifice. Rats were anesthetized using isofluorane inhalation while whole 
blood was taken from tail veins. Whole blood was mixed with Heparin-Leo 
(Leo, Denmark) to prevent anticoagulation. Blood was spun at 2,000g for 10 
minutes for plasma collection. Plasma was then stored at -20°C until assayed 
for glucose concentration using QuantiChromTM Glucose Assay Kit (BioAssay 
Systems, USA). Briefly, plasma (5µL) was added to 500µL of reagent 
provided in kit. The mixture was heated at 100°C for 8 minutes and cooled in 
cold water at 4°C for 4 minutes. The optical absorbance was detected using 
UV spectrophotometer at 630nm. Glucose concentrations were calculated with 
reference to a standard curve. 
2.10.2. Body weight 
Rats’ body weights were recorded thrice weekly throughout entire study.  
2.10.3. Measurement of urinary total protein 
Rats were placed in metabolic cages for 24 hours prior to sacrifice for urine 
collection. Total protein was measured using the Bradford assay. Collected 
urine was mixed well and 10µL of urine was added to 190µL to Bradford 
Protein Assay (Bio-rad). The optical absorbance was detected using UV 
spectrophotometer at 595nm. Urinary protein concentrations were then 
calculated with reference to a standard curve. 
2.10.4. Measurement of urinary albumin 
Urinary albumin levels were measured using Rat Albumin ELISA 
Quantification Set (Bethyl Laboratories Inc, USA). Briefly, antibody was 
added to wells and allowed to incubate at room temperature for 1 hour. The 
plates were washed extensively with wash buffer before blocking solution was 
added to each well. The plate was held in room temperature for another 30 
minutes. The wells were washed and 100µL of rat urine was added to each 
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well. The plate was left in room temperature for 1 hour. Following incubation, 
plates were washed and TMB enzyme substrate solution was added and plate 
was placed in the dark for 15 minutes. The enzymatic reaction was stopped by 
the addition of stop solution. The absorbance was detected using UV 
spectrophotometer at 450nm. Albumin concentrations were calculated with 
reference to a standard curve.   
2.10.5. Measurement of plasma and urinary creatinine 
Measurement of plasma and urinary creatinine was performed using using 
QuantiChromTM Creatinine Assay Kit (BioAssay Systems, USA). Thirty 
microliter of urine was added to 100µL of reagent A and 100µL of reagent B 
and mix by pipetting up and down gently. The mixture was allowed to 
incubate at room temperature, optical density was read immediately (OD0) and 
5 minutes (OD5) at 510nm. The urinary creatinine concentrations were 
calculated by dividing the differences between OD5 and OD0 for samples and 
standards respectively and multiplying by 50. 
2.10.6. Calculation of Creatinine Clearance 
Creatinine Clearance is calculated using the formula below.  
ܥݎ݁ܽݐ݅݊݅݊݁	ܥ݈݁ܽݎܽ݊ܿ݁ ൌ ܷݎ݅݊݁	ܥݎ݁ܽݐ݅݊݅݊݁	ݔ	ܨ݈݋ݓ	ܴܽݐ݈݁ܲܽݏ݉ܽ	ܥݎ݁ܽݐ݅݊݅݊݁  
 
2.11. Measurement of transforming growth factor-β (TGF-β) expression levels 
on PTC 
TGF-β expression level gene expression was measured using primers pairs 
adopted from (211), TGF-β forward primer, 5’ CGA GGT GAC CTG GGC 
ACC ATC CAT GAC 3’, TGF-β reverse primer, 5’ CTG CTC CAC CTT 
GGG CTT GCG ACC CAC 3’, Beta-actin forward primer, 5’ AAC CCT AAG 
GCC AAC CGT GAA AAG 3’, Beta-actin reverse primer, 5’ TCA TGA GGT 
AGT CTG TCA GGT 3’. A cocktail of 5µL of  GoTaq® Colorless Master 
Mix (Promega), 3.2µL nuclease-free water,  0.4µM of each primer was added 
to 1µL of cDNA. Mixture was briefly mixed via gentle pipetting. It was then 
amplified via 94°C for 4 minutes, 35 cycles of 94°C for 1 minute, 60°C for 1 
minute, 72°C for 1 minute and lastly, 72° for 10 minutes. PCR product was 
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then run on 1% agarose gel at 100V for 45 minutes before viewing of PCR 
products using Gel Doc (BioRad).  
2.12. Gene expression analysis 
Total RNA was then converted to complementary DNA (cDNA) using RT2 
PreAMP cDNA Synthesis Kit (SABiosciences, Qiagen) according to 
manufacturer’s protocol. Freshly synthesized cDNA then underwent one 
round of amplification (RT2 PreAMP PCR Mastermix and RT2 PreAMP 
Pathway Primer Mix – CAPR09572) before qPCR. Using customized PCR 
array plates from SABiosciences (Plate ID – CAPR09572), preamplified 
cDNA was added into each well containing specific primers for genes of 
interest. DNA Engine Opticon-2 (BioRad) was used for qPCR.  
2.13. Statistical analysis 
2.13.1. Study design (Sample size and Power) 
Present study adopted a similar diabetes induction protocol from Danda et al 
(183). Sample size and power analysis was then calculated using PASS12 
(Hintze, J. (2013). PASS 12. NCSS, LLC. Kaysville, Utah, USA. 
www.ncss.com.).  
2.13.2. Data statistical analysis methods 
Each sample has its Ct value normalised to its respective average 
housekeeping genes using the formula below.  
∆ܥݐ ൌ ܥݐሺ݃݁݊݁	݋݂	݅݊ݐ݁ݎ݁ݏݐሻ െ ܥݐሺܽݒ݁ݎܽ݃݁	݄݋ݑݏ݁݇݁݁݌݅݊݃	݃݁݊݁ݏሻ 
Gene expression levels of each sample are then calculated via equation below.  
ܧݔ݌ݎ݁ݏݏ݅݋݊	ܮ݁ݒ݈݁ ൌ 2ି∆஼௧ 
These calculated expression levels were then used for the input for statistical 
analyses.  
Data were expressed as mean ± SD based on independent experiments. Tests 
of normality were conducted for experiments to decide a parametric or non-
parametric analysis to be performed. Statistical analysis was performed by 
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independent-samples T-test via IBM SPSS Statistics 20 for the comparison 





3.1. Induction of diabetes 
3.1.1. Diabetes induction success rate 





















Baseline 174.6 ± 6.2 6 0 0 
C1 124.0 ± 10.6 6 0 0 
D1 297.2 ± 17.0 8 8 100 
C2 125 ± 4.3 6 0 0 
D2 310.9 ± 26.9 8 8 100 
 
Table 3.1 listed the success rate of inducing diabetes using the combination of 
HFD-STZ. It was measured that the age-matched control groups C1 and C2 
had no rats with non-fasting plasma glucose above 250mg/dL, indicating no 
rats were diabetic in C1 or C2. On the other hand, all rats which received 
HFD-STZ treatment in groups D1 and D2 had non-fasting plasma glucose 
levels above 250mg/dL, thus indicating HFD-STZ treatment had achieved 
100% diabetes induction rate in D1 and D2 groups.  
3.1.2. Non-fasting plasma glucose 
Non-fasting blood glucose levels were measured and recorded one week 
before and after STZ or vehicle administration, at weeks 8 and 13 of study 
when animals were euthanized. Rats in high fat diet and regular diet groups 
had similar blood glucose concentrations (125.47±16.35 mg/dL and 
130.31±20.30 mg/dL respectively) before administration of STZ or vehicle. 
Non-fasting blood glucose was again measured a week post-STZ or vehicle. 
Figure 3.1 showed a significant increase in blood glucose levels in high fat 
diet group (310.39±48.06 mg/dL) compared to regular diet group 
(124.38±16.37 mg/dL). This pattern was observed when rats were sacrificed at 
week 8 and 13 of study (i.e. 3 and 8 weeks post-STZ injection). This 
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suggested a combination of high fat diet and single dose STZ had successfully 
induced diabetes.  
 
Figure 3.1 - Effect of HFD-STZ on diabetic and control rats' non-fasting 
glucose. A week before STZ or citrate buffer administration, all rats had 
similar non-fasting plasma glucose. A statistically significant difference in 
blood plasma between diabetic and control rats occurred a week after STZ or 
citrate buffer administration. The diabetic rats had non-fasting plasma glucose 
levels 2 times higher than control rats from a week after STZ injection till end 
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3.2. Body weight 
Upon introduction of high fat diet to the diabetic group, the rats had slightly 
higher body weight than the control rats which were fed regular chow. 
Although this pattern was observed a week post STZ injection, the difference 
in body weight was not statistically significant. At the third week after STZ, 
the body weight of diabetic rats increased significantly more in high fat diet 
rats (504±45 g) than the control rats (399±31 g). By eighth week post STZ 
(end of study), diabetic rats weighed 30% more than control rats. The trend of 
body weights of both diabetic and control rats were illustrated in Figure 3.2.  
 
Figure 3.2 - Effect of HFD-STZ on diabetic and control rats’ body weight. 
Both diabetic and control rats had similar body weight a week before STZ or 
citrate buffer administration. There were noted to have statistically significant 
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3.3. Urinary parameters 
Rats were placed in metabolic cages for 24 hour urine collection prior to 
euthanasia. Urinary protein, albumin, creatinine and plasma creatinine were 
calculated to assess renal functions.  
3.3.1. Total urinary protein 
Figure 3.3 shows the total urinary protein levels of the diabetic and control rats 
at 5 weeks before any treatment was initiated, 3 and 8 weeks after STZ or 
citrate buffer administration. It was measured that the rats had a baseline 
reading of 4.83±2.07 mg/dL before commencement of any treatment. It was 
then observed that the total urinary proteins for both diabetic and control rats 
increased to 9.76±4.18 mg/dL and 10.38±3.22 mg/dL respectively at 3 weeks 
after STZ or citrate buffer injection. Both groups had their total urinary protein 
levels dropped to 7.7±3.21 mg/dL for the diabetic group and 8.13±2.04 mg/dL 
by the eighth week post STZ or citrate buffer injection.  
 
Figure 3.3 - Effect of HFD-STZ on diabetic and control rats’ total urinary 
protein. It was observed that both diabetic and control rats had similar total 
urinary protein levels 3 and 8 weeks after STZ or citrate buffer administration. 
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3.3.2. Total urinary albumin 
Figure 3.4 shows the total urinary albumin levels of the diabetic and control 
rats at 5 weeks before any treatment was initiated, 3 and 8 weeks after STZ or 
citrate buffer administration. It was measured that the rats had a baseline 
reading of 1.64±0.73 mg/dL before commencement of any treatment. It was 
then observed that the total urinary proteins for both diabetic and control rats 
rose to 5.86±4.88 mg/dL and 3.34±1.18 mg/dL respectively at 3 weeks after 
STZ or citrate buffer injection. Although diabetic rats had 50% higher in total 
urinary albumin levels than its control counterparts, there was no statistically 
significant difference. Both groups had their total urinary protein levels 
dropped to similar concentrations at 2.79±1.09 mg/dL for the diabetic group 
and 2.78±1.14 mg/dL by the eighth week post STZ or citrate buffer injection.  
 
Figure 3.4 - Effect of HFD-STZ on diabetic and control rats’ urinary albumin. 
By third week post STZ injection, diabetic rats showed an increase of 75% in 
urinary albumin levels than the age-matched controls. However, urinary 
albumin levels for diabetic rats dropped 50% to be similar with control group’ 
urinary albumin level at the 8th week after STZ or citrate buffer injection. 
3.3.3. Creatinine clearance 
Figure 3.5 shows the creatinine clearance of the diabetic and control rats at 5 
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buffer administration. It was measured that the rats had a low baseline reading 
of 0.34±0.23 mg/dL before commencement of any treatment. It was then 
observed that the total urinary proteins for both diabetic and control rats rose 
to 1.93±3.2 mg/dL and 1.17±0.49 mg/dL respectively at 3 weeks after STZ or 
citrate buffer injection Both groups had their total urinary protein levels 
increased in similar patterns to concentrations at 5.23±6.92 mg/dL for the 
diabetic group and 3.84±3.87 mg/dL by the eighth week post STZ or citrate 
buffer injection.  
 
Figure 3.5 – Effect of HFD-STZ on diabetic and control rats’ creatinine 
clearance. While both diabetic and control groups share similar trend in the 
increase of creatinine clearance rates at 3 and 8 weeks post STZ or citrate 
buffer injection, the creatinine clearance rate for diabetic group was slightly 
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3.4. TGF-β expression levels 
Figure 3.6 shows TGF-beta PCR bands intensities in rat renal PTCs. All rat 
cDNA samples were co-amplified with both TGF-beta and housekeeping 
gene, Beta actin. Using Image J (NIH), TGF-beta relative densities were 
calculated after normalising to their respective set of beta-actin. The trend of 
TGF-β expression levels in the diabetic and control groups is depicted in 
Figure 3.7.  
 
Figure 3.6 - The bands intensity of TGF-β and β-actin expression levels on rat 
renal PTCs of baseline, C1, D1, C2 and D2 groups.  
Figure 3.7 shows the relative density of TGF-β of the diabetic and control rats 
at 5 weeks before any treatment was initiated, 3 and 8 weeks after STZ or 
citrate buffer administration. It was measured that the rats had a baseline 
reading of 0.38±0.07 before commencement of any treatment. It was then 
observed that the TGF-β relative densities for both diabetic and control rats 
increased to 1.77±0.31 and 1.03±0.16 respectively at 3 weeks after STZ or 
citrate buffer injection. This difference in TGF-β relative densities in both 
diabetic and control groups had a statistical significance. Both groups had their 
TGF-β relative densities dropped to 1.12±0.18 for the diabetic group and 
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0.93±0.19 for the control group by the eighth week post STZ or citrate buffer 
injection.  
 
Figure 3.7 – Trend of TGF-β expression levels on rat renal PTCs of diabetic 
and control groups at 3rd and 8th week post STZ or citrate buffer injection. 
There was statistically significant difference in TGF-β level between diabetic 
and control group at 3rd week after STZ injection. However, the TGF-β 
expression levels dropped gradually till it was slightly higher than control 
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3.5. Histology analysis 
Three different types of changes were observed in the rats. Chronic 
progressive nephropathy were observed in C1 (n=1), C2 (n=2), D1 (n=2), and 
D2 (n=2) groups. Approximately ten cortical renal tubular profiles had 
variably-sized epithelial cells which were attenuated or swollen with 
basophilic foamy cytoplasm and variably-sized nuclei. The basement 
membranes were moderately thickened and some profiles had dilated lumena. 
However, on a severity scale of 1 to 5, the pathologist graded only 0.5 for 
affected rats. The second change was mineralisation which was found in C1 
(n=1) and D1 (n=1). This particular change was seen in one and two tubule for 
the affected rats in C1 and D1 respectively. This severity was graded 0.25 at 
most according to the pathologist. The last change was mild dilation of 
cortical tubules in one rat from C2. It was a very minimal dilation. Notes from 




3.6. Identification of rat renal PTCs 
Renal PTCs were differentiated from other renal cells by their distinct brush 
border membranes. Figure 3.8 showed the renal PTCs (outlined in red). As 
compared to the other renal cells such as distal tubular cells and glomerulus, 
PTCs' unique brush border membranes can be seen.   
 
Figure 3.8 - Hematoxylin and eosin stained rat kidney section. Rat renal PTCs 




3.7. Minimal number of renal PTCs required for qPCR 
Figure 3.9 showed the total RNA extracted from 3000, 8000 and 18000 renal 
cells respectively. Agilent 2100 Bioanalyzer showed 3000 renal cells were not 
sufficient to generate a detectable reading. 8000 and 18000 renal cells whereas 
yielded similar RNA concentrations (37pg/µL and 36pg/µL respectively).  
 
Figure 3.9 - Total RNA yields extracted from different number of renal cells. 
Three sets of different number (3000, 8000 and 18000) of renal cells were 




3.8. Collection of renal cells via LCM 
Renal proximal tubular cells (PTCs) that were collected and transferred to 
LCM caps were visualized under microscope in Figure 3.10. It was clearly 
shown that only the thermoplastic film of the cap was left after RNA 
extraction, implying majority of renal cells was fully extracted during RNA 
isolation procedure.  
 
Figure 3.10 - Microscopic view of caps containing rat renal PTCs before and 
after total RNA extraction. View on the left refers to H&E stained PTCs 
successfully transferred to HS caps. The right view showed successful lysis of 
cells during total RNA isolation, leaving behind only the thermoplastic film of 





3.9. Assessment of RNA integrity at progressive stages of sample 
preparation 
Fresh tissue section without OCT embedding or H&E stain and unstained 
fresh tissue embedded with OCT embedding generated the best (highest) RIN 
at 8 and 8.1 respectively. RIN for tissue section after embedding and H&E 
staining showed a drop in RIN to 7. As for microdissected renal PTCs 
collected within 15 minutes had a RIN dropped further to 6.2. Lastly, renal 
PTCs collected within 35 minutes and archived kidney tissue showed badly 
degraded RNA quality. The RIN was summarised in Table 3.2.  
Figure 3.11 showed the electrophoresis profiles of RNA integrity generated 
from Agilent 2100 Bioanalyzer. 1: Fresh tissue section without OCT 
embedding and H&E stain. 2: Fresh tissue section with OCT embedding but 
without H&E staining. 3: Fresh tissue section with OCT embedding and H&E 
stain. 4: PTCs collected within 20 minutes. 5: PTCs collected within 40 
minutes. 6: Tissue section stored for 6 months in -80°C. The two distinct 
bands present the 18S and 28S bands which symbolised the intactness of total 
RNA. For samples 1 to 4, relatively clear bands were observed, thus 
correlating to the higher RIN compare to samples 5 and 6.  
Table 3.2 - RNA integrity at progressive stages of sample preparation.  
No. Progressive stages of sample preparation RIN 
1 Fresh kidney tissue section 8.0 
2 Fresh kidney tissue embedded with OCT compound 8.1 
3 Fresh kidney tissue embedded with H&E staining 7.0 
4 Renal PTCs collected within 20 minutes 6.2 
5 Renal PTCs collected within 40 minutes 1.0 





Figure 3.11 - Electrophoresis profiles of 18S and 28S mRNA bands from 
Agilent Bioanalyzer. 1: Fresh tissue section without OCT embedding and 
H&E stain. 2: Fresh tissue section with OCT embedding but without H&E 
staining. 3: Fresh tissue section with OCT embedding and H&E stain. 4: PTCs 
collected within 20 minutes. 5: PTCs collected within 40 minutes. 6: Tissue 




3.10. Effects of modified DNase I treatment on RNA integrity 
The modifications made in DNase I treatment were assessed to see if such 
changes may impact RNA RIN.  
 
Figure 3.12 - Effects of original DNase I treatment on RNA RIN (5 units of 
DNase I enzyme with 15 minutes of incubation period) 
 
 
Figure 3.13 - Effects of modified DNase I treatment on RNA RIN (10 units of 
DNase I enzyme with 30 minutes of incubation period) 
Figures 3.12 and 3.13 showed no distinct difference in RNA RIN profiles after 
the modifications made to DNase I treatment protocol. This suggests no 
degradation was present with the increase in DNase I enzyme units and 




3.11. Effects of modified DNase I treatment on gDNA elimination 
Figure 3.14 shows a decrease in gDNA expression levels after doubling 
DNase I units and treatment period. Using standard manufacturer's protocol, 
presence of gDNA was detected with a Ct value of 25.94. After increasing 
DNase I units and treatment period, gDNA's Ct value increased to above 35, 
implying a reduction in the expression level of gDNA. According to 
manufacturer, Ct value of 35 and above would refer to low to nil expression 
levels. Furthermore, housekeeping gene, Beta-actin Ct value increased from 
21.24 to 33.08 after DNase I treatment modification. 
 
 
Figure 3.14 - Effects of DNase I on the elimination of gDNA. Using standard 
manufacturer's protocol, presence of gDNA was detected with a Ct value of 
25.94. After increasing DNase I units and treatment period, gDNA's Ct value 





3.12. Overall RNA quality control of study groups 
Table 3.3 below states the RNA quality control data of all the rats from 
Baseline, C1, D1, C2 and D2 groups. The total RNA concentrations and purity 
ratios (260/280 and 260/230) of all rat samples were measured using 
NanoDrop 2000 UV-Vis Spectrophotometer. As Agilent 2100 Bioanalyzer is 
not readily available for usage, only selected samples from each study group 
were ran for RIN analyses.  
















1 5330 2.03 1.71 2.1 4.7 
2 7463 1.83 1.71 2.5 6.2 
3 10064 1.81 1.69 3.2 5.7 
4 9239 1.74 1.61 3.9 4.9 
5 10766 1.92 1.91 2.7 Did not measure 
















11 10188 1.78 1.93 3.9 7.0 
12 9318 1.83 1.98 3.9 6.7 
23 8782 1.89 1.88 3.6 Did not measure 
24 7651 1.88 1.96 3.1 Did not measure 
31 4815 1.71 1.91 3.0 Did not measure 
















13 7162 1.72 1.94 3.7 Did not measure 
14 5504 2.64 1.99 2.9 6.0 
25 5782 2.24 1.91 2.6 Did not measure 
26 5885 1.99 1.98 2.5 Did not measure 
33 4430 2.02 1.99 3.1 Did not measure 




















7 7971 1.79 1.97 2.9 7.3 
8 9593 2.10 1.81 3.4 6.6 
15 8870 2.03 1.82 3.8 Did not measure 
16 9461 2.01 1.84 3.7 Did not measure 
19 7826 1.90 1.87 3.1 Did not measure 
20 9402 1.87 1.92 2.9 Did not measure 
27 4444 1.89 1.83 3.6 Did not measure 
















9 7971 1.79 1.97 2.9 Did not measure 
10 9593 2.10 1.81 3.4 6.3 
17 8870 2.03 1.82 3.8 Did not measure 
18 9461 2.01 1.84 3.7 Did not measure 
21 7826 1.90 1.87 3.1 Did not measure 
22 9402 1.87 1.92 2.9 Did not measure 
29 4444 1.89 1.83 3.6 Did not measure 
30 6864 2.14 1.72 4.2 Did not measure 
 
As seen in Table 3.3, the total RNA concentrations extracted for all rat 
subjects had exceeded the minimal requirement of 1ng as advised from 
manufacturer’s protocol. The purity ratios (260/280 and 260/230) readings 
were relatively constant for all samples, and were of good quality readings. 
Therefore, inhibition of reverse transcription was minimised. The RIN 
readings for the selected rat samples were close, ranging from 5.0 to 7.0, thus 




3.13. Gene expression profiles 
3.13.1. Baseline group 
Figure 3.15 below shows the Baseline group’s average Ct values of genes of 
interest and housekeeping genes. According to manufacturer’s protocol, Ct 
values greater than 35 represent genes with an expression level that is too low 
to be quantified. Genes of interest and housekeeping genes had Ct values 
lower than 35. All twenty renal drug transporters under study had shown to 
have Ct values below 35, therefore suggesting the optimized sample 
preparation procedures leading to a total RNA integrity, purity and 
concentration sufficient for downstream qPCR analysis.  
 
Figure 3.15 - Gene expression profile of baseline group (n=6). All Ct values 





3.13.2. Effects of maturation on drug transporters’ gene expression profile on 
control rats 
The effects of maturation on the renal drug transporters were assessed by the 
comparison of C1 (15-week-old rats) and C2 (20-week-old rat) against 
Baseline (7-week-old rats). As seen in Figure 3.16, there were fold changes in 
all renal drug transporters at different time points of this study.  
When compared to the Baseline group, C1 group had 11 renal drug 
transporters (OCT1, OCT3, OCTN1, OCTN2, CNT1, CNT2, OAPT-1, 
OATP-3, BCRP and PGP) which were downregulated and 9 renal drug 
transporters (OCT2, OAT2, OAT3, PEPT1, PEPT2, OAT-K1, MATE1, 
MRP2 and MRP3) which were upregulated. OCT2, PEPT2 and MATE1 had 
upregulated fold changes with statistical significance. OCT2 had 3.465 folds, 
PEPT2 had 3.171 folds and MATE1 had 3.314 folds higher than the Baseline 
group.  
C2 group also shared similar fold changes as C1 when compared to Baseline 
group. C2 had 10 drug transporters (OCT1, OCT3, OCTN1, OCTN2, CNT2, 
OAPT-1, OATP-3, BCRP and PGP) with upregulation and the remaining 10 
drug transporters (OCT2, OAT2, OAT3, CNT1 PEPT1, PEPT2, OAT-K1, 
MATE1. MRP2 and MRP3) being downregulated. However, only PEPT2 and 





Figure 3.16 - The effect of maturation on renal drug transporter expression levels on control rats. Baseline (n=6), C1 (n=6) and C2 (n=6) groups 
represent rats at age 7-week-old, 15-week-old and 20-week-old respectively. Fold changes of C1 and C2 groups were compared to Baseline 


















































































































































3.13.3. Effects of maturation on drug transporters’ gene expression profile on 
diabetic rats 
The effects of maturation on the renal drug transporters were assessed by the 
comparison of D1 (15-week-old diabetic rats) and D2 (20-week-old diabetic 
rats) against Baseline (7-week-old rats). As seen in Figure 3.17 below, there 
were fold changes in all renal drug transporters at different time points of this 
study. 
When compared to the Baseline group, D1 group had 11 renal drug 
transporters (OCT1, OCT3, OCTN1, OCTN2, PEPT1, CNT1, CNT2, OAPT-
1, OATP-3, BCRP and MRP3) which were downregulated and 9 renal drug 
transporters (OCT2, OAT1, OAT2, OAT3, PEPT2, OAT-K1, MATE1, MRP2 
and PGP) which were upregulated. OCT1 and BCRP had statistically 
significant downregulation while OCT2 and MATE1 had upregulation with 
statistically significance.  
D2 group also shared similar fold changes as D1 when compared to Baseline 
group. D2 had 11 drug transporters (OCT2, OAT2, OAT3, PEPT1, PEPT2, 
CNT1, OAT-K1, MATE1, MRP2, MRP3 and PGP) with upregulation and the 
remaining 9 drug transporters (OCT1, OCT3, OCTN1, OCTN2, OAT1, 
CNT2, OATP-1, OATP-3 and BCRP) being downregulated. However, only 
OCT2, PEPT2 and MATE1 generated statistically significant differences 




Figure 3.17 - The effect of maturation on renal drug transporter expression levels on diabetic rats. Baseline (n=6), D1 (n=8) and D2 (n=8) groups 
represent rats at age 7-week-old without receiving any treatment, 15-week-old and 20-week-old diabetic rats respectively. Fold changes of D1 
and D2 groups were compared to Baseline group. Bars represent ±SD of measurements made on 6 to 8 rats. * P < 0.05, values significantly 















































































































































3.13.4. Trends of maturation effects on drug transporters’ gene expression 
profile on control and diabetic rats 
 
Figure 3.18 - Trends of maturation in renal drug transporter expression with 
statistical significance in fold changes in control rats. 
Figure 3.18 illustrates the trends of renal drug transporters with statistically 
significant fold changes when compared to Baseline group. Although OCT2 
showed statistically significant fold change at 15-week-old rats, its expression 
level remained relatively unchanged till 20-week-old. PEPT2 had similar fold 
change at 15-week-old but its fold change dropped from 3.171 to 1.644 at 20 
weeks old. MATE1 also had similar fold change at 3.314 folds upregulation at 
15-week-old and its fold change increased two folds to 6.395 by 20-week-old. 
MRP2 also showed an increasing trend in fold changes. MRP2 had an 
upregulation of 2.528 folds at 15-week-old rats and eventually increased to 



































Figure 3.19 - Trends of maturation in renal drug transporter expression with 
statistical significance in fold changes in diabetic rats. 
Figure 3.19 illustrates the trends of renal drug transporters of diabetic rats at 
age 15-week-old and 20-week-old with statistically significant fold changes 
when compared to Baseline group. It was observed that OCT2 showed 
statistically significant 2.999 fold change at 15-week-old rats, its expression 
level remained relatively unchanged (3.185 folds upregulated) till 20-week-
old. PEPT2 had similar fold change at 15-week-old till 20-week-old from 
2.344 to 2.569. MATE1 had fold change at 3.24 folds upregulation at 15-
week-old and its fold change increased to 5.396 folds by 20-week-old. BCRP 
had a downregulation of 0.106 when compared to Baseline group at 15-week-



































3.13.5. Effects of HFD-STZ on drug transporters expression levels on 
diabetic rats in progressive diabetes 
The effects of HFD-STZ on the renal drug transporters were assessed by the 
comparison of D1 (3 weeks post STZ injection) and D2 (8 weeks post STZ 
injection) against their respective age-matched controls. As seen in Figure 
3.20 below, there were fold changes in all renal drug transporters at different 
time points of this study.  
When compared to its age-matched controls, D1 group had 8 renal drug 
transporters (OCT1, OCT2, OCTN1, OCTN2, OAT2, PEPT1, PEPT2 and 
MRP3) which were downregulated and 12 renal drug transporters (OCT3, 
OAT1, OAT3, CNT1, CNT2, OATP-1, OATP-3, OAT-K1, MATE, BCRP, 
MRP2 and PGP) which were upregulated. On the other hand, D2 had 15 drug 
transporters (OCT2, OCT3, OCTN2, OAT1, OAT2, OAT3, PEPT1, PEPT2, 
CNT1, CNT2, OATP-3, OAT-K1, BCRP, MRP3 and PGP) with upregulation 
and the remaining 5 drug transporters (OCT1, OCTN1, OATP-1, MATE1 and 
MRP2) being downregulated. Despite having a 6.349 folds upregulation for 
OATP-3 for D1 when compared to its age-matched controls, no statistical 
significant was produced for this upregulation. Similar scenarios were seen for 




Figure 3.20 – Effects of HFD-STZ on renal drug transporters expression levels of diabetic rats in progressive diabetes. D1 (n=8) and D2 (n=8) 
are treatment groups which received HFD-STZ. D1 and D2 groups were sacrificed at three- and eight-week post-STZ administration 
respectively. Fold changes of these renal drug transporters from both D1 and D2 were compared to their respective age-matched controls. Bars 












































































































































Effects of HFD-STZ on renal drug transporter gene expression level 
on diabetic rats in progressive diabetes




4.1. Effects of HFD-STZ on blood glucose and body weight 
There are two important factors that contribute to the high blood glucose 
levels in type 2 diabetes. They are the body’s resistance to insulin, basically 
ignoring its insulin secretion and the failed production of insulin by pancreatic 
β cells. As discussed, there were many rodent diabetic models available, such 
as genetically modified and chemically induced models. Although inbred 
diabetic rats inherited hyperglycaemia and/or obesity which bring convenience 
in research studies, they are often pricy and not easy to breed. Therefore, 
developing chemically induced rodent diabetic models allows a shorter 
generation time and economic considerations (212). 
Recent studies reported that high-fat diet for animals developed insulin 
resistance (213, 214). At the same time, low dose STZ was studied to cause 
mild impairment of insulin secretion which is similar to one of the important 
factors of type 2 diabetes (154, 181). Therefore, researchers have started to 
develop a diabetic rat model using a combination of a high-fat diet and low 
dose STZ which mimics type 2 diabetes (154, 183). The current study adopted 
similar methodology by using a high-fat diet (35% fat source from lard) meant 
to induce diabetes with a single low dose (35mg/kg) STZ to not only induce 
diabetes but also to cause diabetic nephropathy (183). 
Hyperglycaemia was observed just one week after STZ administration. One 
week prior to STZ administration, all groups had similar plasma glucose levels 
but diabetic groups had plasma glucose levels doubled after a week of STZ 
administration. This observation continued eight weeks after STZ injection. 
This indicates the stability of hyperglycaemia in diabetic rats in this study. 
This observation was on par with previous publications (154, 183, 212). 
Although plasma glucose levels of controls and diabetes were different in all 
publications, trends were similar. This different glucose levels could be due to 
different high-fat diet types used in respective studies. Furthermore, rats which 
underwent the HFD-STZ treatment developed diabetes, indicating a 100% 
success rate in the induction of diabetes without any casualty. 
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The current study’s diabetic rats showed a gradual increase in body weight 
throughout the study which differed from other researchers’ findings. It was 
demonstrated that a drop in body weight only after the administration of STZ 
and that trend was observed 14 weeks after STZ injection. This gradual 




4.2. Effects of high-fat diet and single dose STZ on renal function 
Renal functions were assessed through creatinine clearance, total urinary 
protein and urinary albumin levels. All groups had statistically significant 
difference in total urinary protein and albumin levels when compared to 
Baseline group. However, when comparing diabetic rats with their age-
matched counterparts, they had slightly lower (but not significant) urinary 
protein levels. As for urinary albumin levels, though diabetic groups had 
higher albumin levels than the age-matched controls, the differences were not 
statistically significant. This may suggest a sign of microalbuminuria 
occurring and may support the finding that microalbuminuria could be a gold 
standard biomarker for nephropathy (215).  
The relative density intensities of TGF-β showed statistically significant 
increase in all groups when compared to the Baseline group. The intensities 
increased when comparing diabetic to control groups with statistically 
significant increase between D1 and C1. However, the intensity of TGF- β in 
D2 reduced. The initial increase in TGF-β expression could be due to the 
damage caused by STZ injection and the eventual drop in TGF-β expression 
may suggest a possibility of the body's protective and/or mechanisms to fight 
the destructive damage caused by STZ initially. Nonetheless, the increased 
TGF-β expression on renal PTCs suggests that tubular injury may occur earlier 
than glomerular damage. Histology analyses did not confirm the induction of 
nephropathy in diabetic rats. The selected rats which suffered chronic 
progressive nephropathy could be due to aging.  
Although present study adopted similar protocol and duration for the induction 
of diabetic nephropathy as seen in Danda et al, diabetic nephropathy was not 
successfully induced. Current study used male Wistar rats instead of male SD 
rats employed in Danda et al's protocol (183) because SD rats were not 
available when current study was initiated.  It was brought into attention that 
such discrepancies were observed in the usage of different mouse strains 
which underwent similar treatments (178). As such, a possible reason for the 
unsuccessful diabetic nephropathy induction could be due to the difference in 
rat strains used in both studies. Alternatively, current study maybe prolonged 
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to determine if the diabetic rats would develop nodular glomerulosclerosis 
which is the hallmark of diabetic nephropathy in humans (183). This 
observation was seen in a genetic rat model of diabetes and kidney disease 
(T2DN/Mcwi strain) developed lesions and glomerulosclerosis only at 18-
month-old (216).   
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4.3. Establishment of protocol for the collection of rat renal proximal tubular 
cells 
Although the modified H&E staining was shorter than a typical H&E staining, 
the modified version had successfully allowed the identification of rat renal 
PTCs.  
LCM had been an extremely valuable technique in the collection of single cell 
population. This had enable scientists and researchers to look into specific cell 
functions, thus providing in depth understanding especially during diseased 
states. However, the minimum number of renal PTCs has to be determined for 
sufficient total RNA yield for qPCR. 8000 and 18000 renal cells showed 
similar total RNA concentrations, suggesting the maximum capacity the RNA 
isolation kit is capable of handling is between 8000 and 18000 cells. As 8000 
renal cells yielded sufficient total RNA for downstream qPCR, the minimal 
number of renal PTCs will be determined at 8000 cells.  
Its integrity and purity were then assessed using Agilent Bioanalyser which 
generates a RIN. RIN was measured at each stage of sample preparation to 
enable an understanding with regards to RNA degradation and also allows any 
modification to be done at specific stage.  
A gradual drop in RIN could be observed during sample preparation though 
several procedures had been optimized such as shortening of H&E stain 
without compromising on the visualization of PTCs, performing staining on 
ice, working within 20 minutes for PTCs collection, additional binding and 
elution steps in the RNA extraction protocol and increasing the DNase I 
treatment period. The precautionary measures were taken to ensure the yield 
of the best RNA quality from the small number of cells. 
It was also demonstrated that total RNA isolated was successfully applied on 
qPCR looking into the gene expression profiles of drug transporters studied to 
be located on rat renal PTC. All genes of interest had Ct values below 35 




4.4. Good RNA quality 
As elaborated previously, it is important to generate a good quality RNA for 
qPCR analyses. Extracted total RNA’s integrity and purity ratios (260/280 and 
260/230) were assessed using Agilent Bioanalyser which generates a RIN. 
RIN was measured at each stage of sample preparation to enable an 
understanding with regards to RNA degradation and also allows any 
modification to be done at specific stage. There was a gradual decrease in RIN 
in the progressive steps of sample preparation. This mild degradation is 
unavoidable as the time required for sample preparation had already been 
shortened. From the data (Table 2.2), it is not recommended to use archived 




4.5. Gene expression analyses 
 
4.5.1. Effects of maturation on renal drug transporters expression levels 
It was observed that maturation had a down regulatory effect on the expression 
of several renal drug transporters in the control rats when compared to the 
Baseline group. These renal drug transporters are OCT1, OCT3, OCTN1, 
OCTN2, CNT2, OAPT-1, OATP-3, BCRP and PGP. On the other hand, 
OCT2, OAT2, OAT3, PEPT1, PEPT2, CNT1, MATE1, MRP2 and MRP3 
showed increase in fold changes when compared to Baseline group.  
It was noted that OCT2, PEPT2 and MATE1 showed statistically significant 
fold changes at C1 (15-week-old rats) when compared to Baseline (7-week-
old) and MRP2 showed statistical significant fold changes at C2 (20-week-old 
rats) when compared to Baseline. OCT2’s and PEPT2’s fold changes then 
dropped by C2 (20-week-old rats). As for MATE1, its fold change increased 
by two times by the time the rats were 20 weeks old.  
The effects of maturation on renal drug transporters’ expression levels on 
diabetic rats were assessed via the comparison of Baseline group. The trend 
profile in fold changes of renal drug transporters in the diabetic group was 
similar to the control groups with a few differences observed.  
Similar to the control group’s maturation profile, D1 (diabetic rats at 15-week-
old) and D2 (diabetic rats at 20-week-old) had down regulations for OCT1, 
OCT3, OCTN1, OCTN2, OATP-1, OATP-3, and BCRP. Renal drug 
transporters OCT2, OAT2, OAT3, CNT1, OAT-K1, MATE1 and MRP2 had 
similar up regulations in both diabetic and control rats. This observation could 
suggest that the HFD-STZ treatment may not have much impact on the 
regulations of gene expressions of these renal drug transporters and these 
down regulations maybe an effect of simply, maturation.  
In contrast, OAT1 showed a consistent down regulation in the control rats. 
However, diabetic rats aged 15-week-olds (D1) showed an increase in fold 
change when compared to Baseline group. However, the expression level 
dropped when the diabetic rats reached 20-week-old (D2). PEPT1 showed a 
drop in fold changes, when the diabetic rats were 15-weeks-old and an 
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upsurge in fold change when diabetic rats were 20-weeks-old. The drop in 
expression level of PEPT1 of diabetic rats at age 15-week-old could be due to 
the effect of STZ administration. However, the effect of STZ may be worn out 
when the diabetic rats reached 20 weeks old, thus explaining the eventual 
rebound of expression level at 20 weeks old. Similar observations were made 
for MRP3’s expression levels in diabetic rats. When compared to control rats 
at 15 weeks old which had an up regulation in MRP3 expression level, the 
diabetic rats at 15 weeks old showed a down regulation instead. However, 
both control and diabetic rats at age 20 weeks old had their MRP3 expression 
level increased. Therefore, this difference in expression trend in control and 
diabetic rats at age 15-week-old may be contributed by the STZ 
administration. PGP on the other hand, showed more drastic fold differences 
between control and diabetic rats. In control rats, PGP’s expression levels 
were down regulated when the control rats were 15 and 20 weeks old. 
However, PGP showed increasing expression levels in the diabetic rats at 15-
week-old and 20-week-old. This contrast was suggested to be the cause of the 




4.5.2. Effects of HFD-STZ on renal drug transporters expression levels in 
diabetic rats in progressive diabetes 
The effects of HFD-STZ on renal drug transporters expression levels in 
diabetic rats in progressive diabetes were compared against their respective 
age-matched controls to remove maturation as a confounder.  
While majority of renal drug transporters were observed to show a minimal of 
2 fold changes when compared to respectively age-matched controls, four 
drug transporters showed notably drastic fold changes in expression levels in 
progressive diabetes. OCT3, OAT1, OATP-3 and PGP showed increasing 
expression levels in an increasing trend from 3-weeks post-STZ till 8-weeks 
post-STZ administration. These renal drug transporters presented an increased 
in expression levels by at least four to eight fold. Although these four 
transporters showed notably drastic fold changes, no statistical significance in 
these fold changes was observed. The statistical significance absence could be 
due to small mean differences in expression levels between the controls and 
diabetics and high SD values (i.e. high coefficient of variation). Furthermore, 
only biological replicates (six to eight rats from various groups) were 
performed and analytical replicate was restricted due to funding limitation. 
Thus, resulting in the lack of statistical significance.  
Nevertheless, these renal drug transporters may play important roles in drug 
efficacy and clearance rats. These four renal drug transporters’ roles and 
participation in drug clearances will be elaborated in chapters 4.5.2.1 to 
4.5.2.4.  
4.5.2.1. OCT3 
There were studies conducted to study the expression levels of OCT in 
diabetic states as these transporters play important roles in the renal 
homeostasis of important cations such as neurotransmitters and also the renal 
clearances of endogenous and exogenous substrates. Male SD rats were 
injected with a high dose (55mg/kg) of STZ and measurement of OCT3 
mRNA expression levels in whole kidney homogenates were assessed in a 
progressive diabetic state (week 4 and week 32 post-STZ). At week 4 after 
STZ administration, OCT3 showed a decrease in mRNA levels when 
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compared to age-matched controls and a slight increase by week 32 (217). The 
current study observed an increase in OCT3 expression by 1.393 folds and 
4.54 folds at week 3 and week 8 post STZ administration respectively. These 
differences in observations in OCT3 expression levels could be due to the 
different methods in inducting diabetes using varying STZ concentrations and 
also the different target sites of the nephron each study targeted at. The 
specific mechanisms by which OCT3 expressions are altered in experimental 
diabetes are currently unclear. It was studied that metformin, an antidiabetic 
drug is actively transported by OCT3. As metformin does not undergo hepatic 
metabolism, it could suggest that drug-drug interaction by the inhibition of 
OCT3 may be crucial (218). Proton pump inhibitors are commonly used in 
metformin-treated patients, therefore these proton pump inhibitors were used 
to test for metformin uptake efficiency via OCT3 transfected cell lines. It was 
found that proton pump inhibitors did significantly inhibit the metformin 
intake by OCT3 (218).  There were studies looking into the transport activity 
of OCT3 using knockout mice models as well. As N-methyl-4-
phenylpyridinium (MPP) is a substrate for rat OCT3, it was showed to have an 
accumulation of MPP in OCT3 knockout model when compared to wild-type 
model (219). This finding may suggest the impact physiological or 
pathological conditions may have on OCT3 expression levels which may in 
turn alter its transport activity, thus affecting the pharmacokinetics of its 
substrates.   
4.5.2.2. OAT1 
Although there is currently no available study performed on the effect of 
diabetes on OAT1 expression in rat kidneys, there were numerous studies on 
animal models with renal impairment caused by cisplatin (anticancer drug). 
The therapeutic use of cisplatin is often limited by its potent side-effects such 
as nephrotoxicity. A particular study used the administration of a single dose 
of cisplatin in rats for the induction of renal damage. It was then demonstrated 
that cisplatin had caused a drop in protein expression level of OAT1 in the 
kidney (220). Di Giusto et al later utilised a mercuric chloride for the 
induction of nephrotoxicity. OAT1 protein expression was observed to be 
increased in total kidney homogenates but decreased in the renal basolateral 
100 
 
membranes (221). These findings supported the hypothesis that drug 
transporters expression levels can be regulated by tissue injury.  Giusto et al 
then suggested that the down regulation of OAT1 expression at the renal 
basolateral membranes might be a defensive mechanism developed to protect 
itself from the mercury injury (220). Differing from the above mentioned 
study, the current study observed an increasing trend in OAT1 expression 
levels throughout progressive diabetes. As the approaches to renal damage and 
cell types analysed were different, it is difficult to conclude the roles OAT1 
may participate under renal damage. Substrates of OAT1 include endogenous 
compounds such as medium chain fatty acids, α-ketoglutarate, citrulline, 
cAMP, cGMP, prostaglandins, urate, and acidic neurotransmitter metabolites. 
OAT1 can also transport exogenous compounds such as antibiotics, antiviral 
drugs, histamine receptor subtype 2 antagonists, diuretics, and non-steroidal 
anti-inflammatory drugs. As OAT1 covers a wide range of substrates, its role 
in the mediation of its substrates is important, especially under abnormal 
physical conditions.  
4.5.2.3. OATP-3 
Most OATPs are expressed in many tissues such as the brain, lungs, heart, 
intestines, kidneys, placenta, and testes and abundantly in liver (71). They play 
roles in the uptake of drugs from blood to hepatocytes. Depending on the 
xenobiotics’ characteristics; these transporters may play important roles in the 
systemic clearance of the drug. For example, OATPs function to excrete drugs 
into urines where they are expressed in kidneys. Similarly, these transporters 
may affect drug distribution in the brain and central nervous system (72). 
There is currently no study on OATP-3 renal expression levels in diabetic rats 
and limited research was done on the analysis of OATP-3 expression levels 
under diseased state. It was observed that intestinal OATP-3 had unchanged 
protein expression under chronic renal failure (222). In the current study, 
OATP-3 had shown increases of approximately six folds at three weeks after 
STZ administration and almost eight folds by the end of study (eight weeks 
after STZ administration). OATPs are sodium-independent transport systems, 
which utilise the anion exchange, coupling the cellular uptake of organic 
compounds with the efflux of biocarbonate, glutathione and its conjugates and 
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also a wide spectrum of amphilipathic organic compounds such as bile salts, 
steroid hormones and conjugates, thyroid hormones, organic cations and 
exogenous compounds such as HMG-CoA reductase inhibitor pravastatin, 
antihistamine fexofenadine (70). As mentioned above that OATPs function to 
excrete wastes into the urine, the drastic increase in expression levels under 
diabetic condition observed in the current study may suggest a form of 
compensatory mechanism to increase excretion of waste.  
4.5.2.4. PGP 
Early studies showed that PGP protein level was low in most tissues but 
present in higher amounts at the apical surface of epithelial cells at colon, 
brush border membrane of small intestine, pancreas, biliary canalicular 
membrane of hepatocytes, endothelial cells at the BBB and kidney PTCs (95). 
These tissue localizations suggest the role PGP play in the protection of organs 
from toxic xenobiotics and metabolites. PGP has broad substrate specificity 
for structurally divergent compounds. The substrates are generally 
hydrophobic and some are cationic compounds. Some examples of PGP 
substrates are natural products, anticancer drugs, steroids, fluorescent dyes, 
linear and cyclic peptide and ionophores.  
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Tramonti et al induced diabetes in SD female rats using a combination of 
uninephrectomy and 60mg/kg of STZ. These rats were sacrificed two weeks 
after the onset of diabetes. An upregulation in PGP mRNA levels under 
hyperglycaemic condition was then observed (223). In another study, the PGP 
levels were examined in rats with reduced renal mass in a progressive manner 
at week 3 and 6 after subtotal nephrectomy. An increase in PGP mRNA levels 
was observed in both time points. However, both studies measured the PGP 
mRNA levels in whole kidney homogenate instead of specific cell population 
(224). The current study shares similar findings of upregulation of PGP in 
diabetic rats in progressive diabetes despite those only renal PTCs were 
analysed. These similarities in results may suggest the extreme sensitivity of 
PGP to pathobiological conditions and indicate such subnormal situations 
maybe a stimulus to tubular cells to increase PGP production as a form of 




5. CONCLUSIONS AND FUTURE DIRECTIONS 
In conclusion, the current study had successfully optimized a protocol suitable 
for the collection of rat renal PTCs via the usage of LCM, followed by 
assurance of good quality total RNA suitable for qPCR analysis. This study 
had successfully demonstrated the usage of the above techniques on the study 
of gene expressions of drug transporters located on rat renal PTCs. This 
optimization is able to allow interested scientists or researchers to utilize such 
procedures for the study of expression levels of other genes.  
The current study had attempted to induce diabetic nephropathy using the 
combination of HFD-STZ on male Wistar rats. Although hyperglycaemia was 
constant for diabetic rats after the administration of STZ till the end of study, 
renal function tests showed no signs of diabetic nephropathy. However, TGF-
β expression levels were found to be higher in diabetic rats, suggesting the 
possibility of the occurrence of tubular injury earlier than glomerular damage 
in a diabetic condition.   
Although the combination of HFD and single low dose STZ of 35mg/kg did 
induce hyperglycaemia in male Wistar rats, this method did not induce clinical 
diabetic nephropathy. Urinary protein, albumin levels and creatinine 
clearances in diabetic rats showed no statistically significant differences with 
their age-matched counterparts. However, TGF-β expressions in PTCs were 
higher in diabetic rats than the age-matched controls, implying the possibility 
of occurrence of subclinical tubular injury may occur earlier than glomerular 
damage in diabetes (123).  
In this study, differential gene expression levels of drug transporters in 
progressive diabetes and maturation were analyzed. There were notably 
differences in trends of changes with reference to previous studies. This 
difference could be due to the different induction method for diabetes, the 
particular rodent stain used, or the type of cell or tissue used in the gene 
expression studies. 
Present study looked into effects of maturation and/or HFD-STZ on renal drug 
transporters expressed on rat renal PTCs. OCT2, PEPT2, MATE1 and MRP2 
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were the transporters with statistical significant fold changes in C1 and C2 
groups when compared to Baseline group. As for D1 and D2 groups when 
compared to Baseline group, OCT2, PEPT2, MATE1 and BCRP were the 
drug transporters with statistical significant fold changes.  
We also looked into the effects of the combination of HFD-STZ treatment had 
on drug transporters expression levels during progressive diabetes. Although 
there was no statistical significant fold change in the drug transporters during 
progressive diabetes, OCT3, OAT1, OATP-3 and PGP were highlighted for 
their consistent changes in gene expression during progressive diabetes.  
Present study offered a novel insight into the changes in gene expression 
levels of drug transporters expressed in rat renal PTCs under diabetic 
conditions. Furthermore, LCM and qPCR protocols had been optimized to 
allow an efficient qPCR analysis.  
Present study had initially budgeted for analytical duplicates for each rat but 
logistics were restricted due to the costly LCM procedures. Although many 
literatures had published on the usage of low number of cells collected via 
LCM for qPCR analyses, it was through optimisation that a minimum of 8000 
renal PTCs were required for downstream qPCR assays for current study. This 
big number of cells required multiple LCM sessions for a single rat. Therefore, 
with the limited budget, only biological replicates were achievable.  
It was observed that male SD rats which received HFD-STZ treatment 
developed glomerular lesions, indicating an extent of renal damage under 
hyperglycaemic conditions (183). Present study utilised male Wistar rats 
instead of supposedly SD rats due to the shortage of rats available. Therefore, 
a difference in rat strain used could contribute to the development of renal 





Different methodologies for the induction of diabetic nephropathy may be 
considered to induce pathological and biochemical alterations such as 
metabolic abnormalities and glomerular lesions. Previous researchers utilized 
a combination of nephrectomy and injection of STZ in male Wistar rats which 
allowed manifestations of nephrotic syndrome, azotemia, hyperglycaemia, and 
diffuse lesions and coagulation in glomeruli that were observed in patients 
with diabetic nephropathy (187). As mentioned above, male SD rats can be 
utilized in similar study design to duplicate similar results seen in Danda et 
al’s study (183).  Otherwise, current study maybe prolonged to determine if 
the diabetic rats would develop nodular glomerulosclerosis which is the 
hallmark of diabetic nephropathy in humans (183). This observation was seen 
in a genetic model of diabetes and kidney disease (T2DN/Mcwi strain) 
developed lesions and glomerulosclerosis only at 18-month-old (216).  
Changes in drug transporters’ expression level may affect therapeutic 
outcomes; therefore animal models may be developed for the study of 
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1. Tissue processing schedule (Tissue-TEK ® VIP 5TM) 
Step No. Solution 
1 70% Ethanol 
2 80% Ethanol 
3 95% Ethanol 
4 95% Ethanol 
5 100% Ethanol 
6 100% Ethanol 




11 Paraffin wax 
12 Paraffin wax 
13 Paraffin wax 
14 Paraffin wax 
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2. Automated schedule hematoxylin and Eosin stain for paraffin sections 
(Leica autoStainer XL) 
Step No. Reagents Time 
1 Xylene 5 min 
2 Xylene 5 min 
3 100% Ethanol 2 min 
4 100% Ethanol 2 min 
5 100% Ethanol 2 min 
6 95% Ethanol 2 min 
7 70% Ethanol 2 min 
8 Gentle running water 2 min 
9 Hematoxylin 2 4 min 
10 Gentle running water 2 min 
11 Clarifier 2 2 min 
12 Gentle running water 2 min 
13 Bluing Solution 2 min 
14 Gentle running water 2 min 
15 70% Ethanol 2 min 
16 Esoin Y/ Phloxine Solution 2 min 
17 70% Ethanol 2 min 
18 95% Ethanol 2 min 
19 100% Ethanol 2 min 
20 100% Ethanol 2 min 
21 100% Ethanol 2 min 
22 Xylene 2 min 
23 Xylene 2 min 





3. Hand-written notes by pathologist (Dr. Ralph Bunte) on pathological 

















5. Ct values of all rats in Baseline group 
Rat ID 
Gene 1 2 3 4 5 6 
OCT1 31.64 33.63 33.27 18.22 24.10 22.60 
OCT2 37.69 39.16 38.14 14.51 21.18 19.63 
OCT3 32.62 30.54 27.54 28.69 30.06 30.35 
OCTN1 39.07 36.98 25.39 21.20 25.66 24.73 
OCTN2 35.26 34.37 24.36 19.13 25.18 22.43 
OAT1 34.29 33.31 34.95 23.26 25.57 25.81 
OAT2 36.65 35.47 36.49 21.35 31.44 25.63 
OAT3 37.83 40.00 39.40 20.10 26.35 22.41 
PEPT1 39.29 40.00 40.00 26.70 40.00 28.31 
PEPT2 32.34 33.83 40.00 18.29 25.24 22.25 
CNT1 33.13 34.97 38.03 24.03 30.07 27.86 
CNT2 31.94 31.33 34.09 25.01 35.96 26.94 
OATP-1 37.01 35.42 38.64 15.89 21.75 20.27 
OATP-3 30.19 35.12 33.90 29.35 32.29 29.47 
OAT-K1 37.02 38.88 3.71 14.32 20.01 19.38 
MATE 32.86 31.42 35.97 17.52 25.40 22.53 
BCRP 34.44 35.38 36.53 18.10 23.29 21.51 
MRP2 38.88 38.88 40.00 22.23 27.55 26.19 
MRP3 36.58 38.56 35.26 23.18 29.20 26.85 
PGP 35.08 36.89 36.60 21.98 28.25 27.63 
ACTB 33.03 32.70 33.88 15.42 23.08 19.39 
GAPDH 27.11 27.44 29.18 16.75 21.15 19.40 
PPIA 23.57 26.23 28.15 14.20 19.66 18.22 
PGK1 21.90 31.07 32.65 15.39 20.20 19.26 
18SrRNA 22.25 25.34 26.96 8.34 16.69 11.58 
gDNA 40.00 40.00 40.00 40.00 40.00 40.00 
RTC 37.32 38.92 38.29 25.41 30.40 29.51 
RTC 32.56 39.00 34.19 25.33 30.18 29.76 
RTC 36.77 34.40 28.93 25.36 30.22 29.33 
PPC 16.95 17.09 17.31 19.56 19.72 19.92 
PPC 16.28 16.43 17.47 19.15 19.46 19.77 





6. Ct values of all rats in C1 (control rats aged 15-week-old)  
Rat ID 
Gene 11 12 23 24 31 32 
OCT1 28.11 18.39 28.41 26.82 26.98 25.53 
OCT2 23.36 13.87 23.23 22.59 22.63 19.51 
OCT3 31.38 28.17 32.18 33.19 31.39 33.41 
OCTN1 27.70 21.69 30.76 29.21 28.23 29.92 
OCTN2 25.52 18.34 26.36 26.04 26.51 24.08 
OAT1 27.03 24.21 31.43 30.48 28.45 30.73 
OAT2 28.55 20.43 31.38 29.84 28.57 26.53 
OAT3 28.65 19.51 32.40 27.36 27.94 26.89 
PEPT1 40.00 26.46 40.00 30.88 40.00 30.24 
PEPT2 25.25 16.43 26.42 25.47 26.54 24.68 
CNT1 31.57 23.21 31.92 31.04 30.27 27.05 
CNT2 29.89 23.68 34.78 33.29 32.89 28.31 
OATP-1 24.76 16.21 27.52 25.08 25.16 24.09 
OATP-3 32.08 28.32 32.81 31.92 29.81 34.08 
OAT-K1 23.30 15.05 23.99 23.56 23.22 21.11 
MATE 26.34 16.10 26.30 24.56 25.05 21.37 
BCRP 25.98 17.05 25.77 25.35 25.07 22.39 
MRP2 40.00 21.20 30.33 29.69 29.51 26.17 
MRP3 28.64 21.09 32.09 29.09 38.35 26.59 
PGP 32.76 22.39 30.59 29.50 33.18 29.53 
ACTB 23.99 15.02 24.44 23.54 22.39 21.13 
GAPDH 24.75 15.79 25.66 24.43 24.15 23.88 
PPIA 22.71 14.29 22.47 21.56 21.57 18.68 
PGK1 23.90 16.24 24.65 23.74 23.74 21.99 
18SrRNA 18.52 7.64 18.68 15.52 15.45 14.45 
gDNA 40.00 40.00 40.00 40.00 40.00 40.00 
RTC 31.72 23.45 30.10 29.84 29.91 28.17 
RTC 32.46 23.36 29.57 30.27 30.16 28.13 
RTC 32.35 23.28 29.86 29.88 29.84 27.94 
PPC 19.56 19.55 19.68 19.49 19.30 20.01 
PPC 19.58 19.17 19.63 19.22 19.29 19.60 




7. Ct values of all rats in C2 (control rats aged 20-week-old)  
Rat ID 
Gene 13 14 25 26 33 34 
OCT1 23.71 28.14 26.91 25.73 28.57 33.23 
OCT2 19.45 21.82 20.84 22.04 23.88 27.2 
OCT3 29.82 32.43 32.2 30.14 30.73 34.97 
OCTN1 26.21 31.94 32.42 27.85 31.16 34.79 
OCTN2 23.73 25.45 25.16 26.24 27.65 28.96 
OAT1 28.30 30.72 32.85 29.57 32.08 35.33 
OAT2 27.23 28.78 28.47 27.62 29.11 33.45 
OAT3 23.63 29.25 28.13 25.52 29.69 33.16 
PEPT1 29.40 36.93 30.08 30.87 30.94 35.9 
PEPT2 22.30 26.62 25.72 25.13 26.54 30.82 
CNT1 27.60 27.65 28.52 29.92 32.98 35.32 
CNT2 27.28 28.90 29.77 32.64 33.69 39.62 
OATP-1 21.87 28.32 25.5 25.32 28.1 32.12 
OATP-3 34.52 33.82 34.69 32.22 35.1 37.12 
OAT-K1 20.15 22.25 21.65 21.4 25.53 27.51 
MATE 22.58 22.59 22.94 24.38 22.84 29.07 
BCRP 22.17 22.85 22.92 22.39 22.81 28.72 
MRP2 26.13 28.02 26.73 29.28 28.37 33.07 
MRP3 26.88 27.25 27.17 29.83 29.03 33.18 
PGP 26.33 30.51 29.38 32.2 30.88 36.23 
ACTB 20.83 23.41 22.09 23.05 24.81 28.55 
GAPDH 20.85 25.52 24.53 20.25 20.97 27.88 
PPIA 19.01 19.83 19.85 19.86 20.93 25.79 
PGK1 20.39 24.07 22.86 21.52 23.62 28.74 
18SrRNA 11.98 18.57 16.03 17.9 19.56 23.17 
gDNA 40.00 40.00 40.00 40.00 40.00 40.00 
RTC 28.46 29.25 30.76 30.38 32.2 33.13 
RTC 28.40 28.57 31.61 30.2 32.75 33.24 
RTC 28.70 28.94 31.65 30.12 31.8 39.08 
PPC 19.98 19.36 19.53 19.28 19.61 19.27 
PPC 20.02 19.12 19.66 18.9 19.25 19.17 





8. Ct values of all rats in D1 (diabetic rats aged 15-week-old)  
Rat ID 
Gene 7 8 15 16 19 20 27 28 
OCT1 30.33 20.54 26.00 27.22 27.77 26.98 26.59 27.03 
OCT2 25.76 14.78 21.13 21.97 22.52 22.48 21.66 21.26 
OCT3 32.04 28.66 31.30 31.95 33.37 31.09 31.90 35.81 
OCTN1 30.81 22.34 27.94 31.11 31.03 31.96 26.91 29.11 
OCTN2 27.86 19.71 25.14 25.79 27.38 25.49 24.80 24.40 
OAT1 27.20 24.57 29.52 31.45 31.69 30.41 28.00 30.48 
OAT2 32.48 21.50 30.03 28.37 29.47 28.68 28.55 28.15 
OAT3 29.08 21.48 25.64 28.05 29.89 29.55 26.89 25.91 
PEPT1 40.00 28.46 40.00 40.00 40.00 37.00 34.55 30.61 
PEPT2 28.96 18.07 24.27 25.29 25.43 26.67 25.13 24.47 
CNT1 35.12 23.42 30.02 30.85 29.67 29.07 28.28 27.65 
CNT2 35.69 23.66 28.41 29.22 34.80 29.17 29.90 28.60 
OATP-1 25.77 18.05 24.24 26.00 25.74 26.44 24.61 23.81 
OATP-3 29.13 28.27 29.07 30.12 34.63 33.87 31.15 34.53 
OAT-K1 24.60 15.52 21.83 22.09 22.58 22.88 21.75 21.52 
MATE 28.28 16.99 23.71 25.51 25.78 23.44 23.26 22.52 
BCRP 27.95 17.26 23.70 24.54 25.17 23.71 22.97 23.36 
MRP2 39.83 21.74 28.29 28.60 28.85 27.54 27.24 27.66 
MRP3 35.56 22.52 29.17 29.94 36.32 28.02 28.67 27.78 
PGP 34.05 23.13 28.60 28.70 29.84 28.99 30.00 30.38 
ACTB 25.19 16.07 22.50 22.65 23.97 23.15 22.08 22.41 
GAPDH 27.96 16.76 22.35 24.01 24.80 25.15 22.54 23.05 
PPIA 24.25 14.71 21.63 21.17 21.35 20.58 20.49 20.37 
PGK1 25.27 16.19 22.93 23.22 23.68 24.26 21.95 22.28 
18SrRNA 21.39 9.32 15.62 18.20 18.25 17.40 13.59 13.28 
gDNA 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
RTC 33.59 23.74 31.66 30.37 28.37 29.54 29.84 29.08 
RTC 33.39 23.40 31.01 30.26 28.76 29.40 30.20 29.36 
RTC 32.17 23.32 30.58 30.66 28.66 29.20 29.13 28.75 
PPC 19.35 19.27 19.62 19.71 19.60 19.51 18.93 19.33 
PPC 19.10 18.95 19.16 19.71 19.24 19.16 19.67 18.93 





9. Ct values of all rats in D2 (diabetic rats aged 20-week-old)  
Rat ID 
Gene 9 10 17 18 21 22 29 30 
OCT1 28.75 28.96 30.93 30.53 26.22 29.51 34.69 28.89 
OCT2 23.68 22.51 26.09 25.07 20.25 23.52 31.63 22.53 
OCT3 32.57 31.96 40.00 40 31.5 30.98 32.34 35.25 
OCTN1 30.34 33.34 33.33 33.07 29.56 30.47 40 32.37 
OCTN2 26.85 26.63 27.35 27.86 23.98 28.5 29.35 25.53 
OAT1 30.43 32.13 35.45 33.8 29.51 31.2 31.8 33.25 
OAT2 29.93 29.73 31.92 31.29 27.74 29.62 33.87 29.45 
OAT3 26.76 28.92 29.46 29.87 27.24 28.54 38.61 29.62 
PEPT1 40.00 31.33 35.70 38.36 28.88 30.76 34.87 32.16 
PEPT2 25.81 27.27 28.54 27.04 25.22 26.19 33.47 26.63 
CNT1 30.94 29.23 33.28 33.12 26.85 34.59 35.26 29.08 
CNT2 28.95 30.69 33.32 33.56 27.7 36 36.76 30.79 
OATP-1 26.83 29.14 29.13 28.89 25.4 26.56 36 27.93 
OATP-3 32.86 34.79 37.63 35.85 31.62 31.52 34.14 33.54 
OAT-K1 25.52 23.74 27.95 27.18 21.22 25.36 31.29 24.42 
MATE 23.80 23.14 27.00 26.02 20.76 22.4 28.51 23.26 
BCRP 26.41 23.87 27.62 27.32 21.96 22.91 27.2 24.8 
MRP2 33.31 29.60 31.49 31.61 26.26 28.44 33.58 29.5 
MRP3 29.50 27.20 32.28 31.19 26.25 37.39 37.46 28.74 
PGP 29.48 30.42 32.85 32.02 30.35 33.9 31.47 31.67 
ACTB 24.85 24.33 26.64 26.98 21.94 24.63 31.5 24.55 
GAPDH 24.36 26.38 27.25 26.78 23.47 20.99 26.14 25.55 
PPIA 22.89 20.69 24.62 24.22 18.86 20.73 26.15 21.53 
PGK1 25.06 24.64 26.46 25.84 22.34 23.35 29.58 24.67 
18SrRNA 17.16 19.68 19.60 19.95 15.21 18.68 26.44 18.52 
gDNA 40.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 
RTC 31.10 29.34 31.61 30.79 30.15 32.25 33.16 29.75 
RTC 30.43 29.58 31.47 32.52 30.18 33.54 33.36 29.62 
RTC 30.71 29.44 32.21 31.55 29.54 31.4 32.72 29.75 
PPC 19.53 19.51 19.75 19.54 19.15 19.66 19.28 19.01 
PPC 19.44 19.23 19.56 19.11 19.04 19.3 19.29 18.78 




10. Statistical analysis on effects of maturation on drug transporters 
expression levels on C1 group when compared to Baseline group 




values Lower Upper 
OCT1 
Baseline 0.0518 0.0363 
0.0240 -0.0140 0.0620 0.169 
C1 0.0278 0.0074 
OCT2 
Baseline 0.2416 0.3024 
-0.5957 -1.0229 -0.1684 0.011 
C1 0.8373 0.3593 
OCT3 
Baseline 1.0683 2.4903 
1.0673 -1.5461 3.6807 0.342 
C1 0.0010 0.0010 
OCTN1 
Baseline 4.5539 11.1356 
4.5442 -7.1419 16.2303 0.363 
C1 0.0097 0.0116 
OCTN2 
Baseline 9.3047 22.7364 
9.2307 -14.6296 33.0911 0.366 
C1 0.0740 0.0458 
OAT1 
Baseline 0.0174 0.0170 
0.0062 -0.0179 0.0303 0.580 
C1 0.0112 0.0203 
OAT2 
Baseline 0.0053 0.0047 
-0.0037 -0.0103 0.0029 0.242 
C1 0.0089 0.0055 
OAT3 
Baseline 0.0109 0.0135 
-0.0021 -0.0160 0.0118 0.744 
C1 0.0130 0.0072 
PEPT1 
Baseline 0.0004 0.0004 
-0.0001 -0.8511 0.0007 0.793 
C1 0.0005 0.0007 
PEPT2 
Baseline 0.0317 0.0142 
-0.0689 -0.1331 -0.0047 0.040 
C1 0.1006 0.0614 
CNT1 
Baseline 0.0040 0.0042 
0.0011 -0.0033 0.0055 0.594 
C1 0.0029 0.0024 
CNT2 
Baseline 0.0377 0.0590 
0.0356 -0.0263 0.0975 0.199 
C1 0.0021 0.0027 
OATP1 
Baseline 1.5963 3.5391 
1.4753 -2.2386 5.1892 0.354 
C1 0.1211 0.0810 
OATP3 
Baseline 0.0211 0.0306 
0.0200 -0.0122 0.0521 0.172 
C1 0.0011 0.0011 
OAT-K1 
Baseline 0.3823 0.4696 
-0.0742 -0.5669 0.4185 0.726 
C1 0.4565 0.1581 
MATE 
Baseline 0.0515 0.0509 
-0.1192 -0.2366 -0.0017 0.047 
C1 0.1707 0.1186 
BCRP 
Baseline 1.5526 3.6796 
1.4295 -2.4319 5.2909 0.385 
C1 0.1232 0.0466 
MRP2 
Baseline 0.0023 0.0022 
-0.0035 -0.0083 0.0012 0.128 
C1 0.0058 0.0047 
MRP3 
Baseline 0.0060 0.0114 
-0.0011 -0.0128 0.0107 0.841 
C1 0.0071 0.0061 
PGP 
Baseline 0.0041 0.0038 
0.0015 -0.0026 0.0056 0.436 




11. Statistical analysis on effects of maturation on drug transporters 
expression levels on C2 group when compared to Baseline group 




values Lower Upper 
OCT1 
Baseline 0.0518 0.0363 
-0.0329 -0.0050 0.0709 0.077 
C2 0.0188 0.0077 
OCT2 
Baseline 0.2416 0.3024 
-0.5079 -0.9992 -0.0167 0.044 
C2 0.7496 0.4474 
OCT3 
Baseline 1.0683 2.4903 
1.0668 -1.1985 3.3321 0.319 
C2 0.0015 0.0012 
OCTN1 
Baseline 4.5539 11.1356 
4.5508 -7.1353 16.2369 0.363 
C2 0.0031 0.0023 
OCTN2 
Baseline 9.3047 22.7364 
9.2271 -11.4548 29.9091 0.344 
C2 0.0776 0.0817 
OAT1 
Baseline 0.0174 0.0170 
0.0157 -0.0022 0.0336 0.074 
C2 0.0017 0.0010 
OAT2 
Baseline 0.0053 0.0047 
-0.0021 -0.0072 0.0030 0.383 
C2 0.0074 0.0031 
OAT3 
Baseline 0.0109 0.0135 
-0.0049 -0.0213 0.0116 0.526 
C2 0.0158 0.0121 
PEPT1 
Baseline 0.0004 0.0004 
-0.0008 -0.0017 0.0001 0.069 
C2 0.0012 0.0008 
PEPT2 
Baseline 0.0317 0.0142 
-0.2043 -0.0393 -0.0015 0.037 
C2 0.0522 0.0151 
CNT1 
Baseline 0.0040 0.0042 
-0.0021 -0.0112 0.0070 0.621 
C2 0.0061 0.0090 
CNT2 
Baseline 0.0377 0.0590 
0.0351 -0.0268 0.0970 0.205 
C2 0.0026 0.0039 
OATP1 
Baseline 1.5963 3.5391 
1.5560 -2.1580 5.2701 0.331 
C2 0.0403 0.0337 
OATP3 
Baseline 0.0211 0.0306 
0.0208 -0.0113 0.0530 0.157 
C2 0.0003 0.0003 
OAT-K1 
Baseline 0.3823 0.4696 
-0.1655 -0.6805 0.3495 0.490 
C2 0.5478 0.3162 
MATE 
Baseline 0.0515 0.0509 
-0.2778 -0.5857 0.0301 0.069 
C2 0.3293 0.2940 
BCRP 
Baseline 1.5526 3.6796 
1.1957 -2.6645 5.0558 0.463 
C2 0.3570 0.2179 
MRP2 
Baseline 0.0023 0.0022 
-0.0096 -0.0169 -0.0029 0.019 
C2 0.0119 0.0070 
MRP3 
Baseline 0.0060 0.0114 
-0.0059 -0.0203 0.0085 0.385 
C2 0.0119 0.0110 
PGP 
Baseline 0.0041 0.0038 
0.0016 -0.0022 0.0054 0.370 
C2 0.0025 0.0016 
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12. Statistical analysis on effects of maturation on drug transporters 
expression levels on D1 group when compared to Baseline group 




values Lower Upper 
OCT1 
Baseline 0.0518 0.0363 
0.0302 -0.0078 0.0681 0.098 
D1 0.0216 0.0089 
OCT2 
Baseline 0.2416 0.3024 
-0.4830 -0.7936 -0.1723 0.005 
D1 0.7246 0.2327 
OCT3 
Baseline 1.0683 2.4903 
1.0669 -1.5465 3.6803 0.342 
D1 0.0014 0.0022 
OCTN1 
Baseline 4.5539 11.1356 
4.5482 -7.1378 16.2343 0.363 
D1 0.0056 0.0050 
OCTN2 
Baseline 9.3047 22.7364 
9.2427 -14.6177 33.1030 0.365 
D1 0.0621 0.0320 
OAT1 
Baseline 0.0174 0.0170 
-0.0084 -0.6980 0.0530 0.771 
D1 0.0257 0.0668 
OAT2 
Baseline 0.0053 0.0047 
-0.0012 -0.0059 0.0035 0.602 
D1 0.0064 0.0034 
OAT3 
Baseline 0.0109 0.0135 
-0.0084 -0.0272 0.0103 0.345 
D1 0.0194 0.0174 
PEPT1 
Baseline 0.0004 0.0004 
0.0003 -0.0001 0.0006 0.178 
D1 0.0001 0.0003 
PEPT2 
Baseline 0.0317 0.0142 
-0.0427 -0.0714 -0.0139 0.008 
D1 0.0744 0.0326 
CNT1 
Baseline 0.0040 0.0042 
0.0001 -0.0039 0.0042 0.937 
D1 0.0039 0.0026 
CNT2 
Baseline 0.0377 0.0590 
0.0344 -0.0275 0.0963 0.212 
D1 0.0033 0.0028 
OATP1 
Baseline 1.5963 3.5391 
1.4651 -2.2484 5.1787 0.357 
D1 0.1312 0.1568 
OATP3 
Baseline 0.0211 0.0306 
0.0138 -0.0188 0.0464 0.353 
D1 0.0073 0.0174 
OAT-K1 
Baseline 0.3823 0.4696 
-0.2833 -0.7180 0.1513 0.181 
D1 0.6656 0.2763 
MATE 
Baseline 0.0515 0.0509 
-0.1153 -0.2173 -0.0134 0.030 
D1 0.1668 0.1050 
BCRP 
Baseline 1.5526 3.6796 
1.3880 -2.4734 5.2494 0.398 
D1 0.1647 0.0687 
MRP2 
Baseline 0.0023 0.0022 
-0.0065 -0.0122 -0.0008 0.029 
D1 0.0088 0.0067 
MRP3 
Baseline 0.0060 0.0114 
0.0014 -0.0084 0.0112 0.764 
D1 0.0046 0.0052 
PGP 
Baseline 0.0041 0.0038 
-0.0002 -0.0043 0.0039 0.914 




13. Statistical analysis on effects of maturation on drug transporters 
expression levels on D2 group when compared to Baseline group 
 







Baseline 0.0518 0.0363 
0.0373 -0.0007 0.0753 0.053 
D2 0.0145 0.0049 
OCT2 
Baseline 0.2416 0.3024 
-0.5279 -1.0511 -0.0047 0.048 
D2 0.7695 0.5230 
OCT3 
Baseline 1.0683 2.4903 
1.0616 -1.5519 3.6750 0.344 
D2 0.0067 0.0167 
OCTN1 
Baseline 4.5539 11.1356 
4.5516 -7.1345 16.2377 0.363 
D2 0.0023 0.0017 
OCTN2 
Baseline 9.3047 22.7364 
9.1679 -14.6924 33.0283 0.369 
D2 0.1368 0.1140 
OAT1 
Baseline 0.0174 0.0170 
0.0069 -0.0183 0.0321 0.562 
D2 0.0105 0.0241 
OAT2 
Baseline 0.0053 0.0047 
-0.0040 -0.0090 0.0010 0.104 
D2 0.0093 0.0039 
OAT3 
Baseline 0.0109 0.0135 
-0.1215 -0.0347 0.0104 0.263 
D2 0.0231 0.0223 
PEPT1 
Baseline 0.0004 0.0004 
-0.0020 -0.0044 0.0005 0.108 
D2 0.0023 0.0027 
PEPT2 
Baseline 0.0317 0.0142 
-0.0498 -0.1049 0.0054 0.073 
D2 0.0815 0.0602 
CNT1 
Baseline 0.0040 0.0042 
-0.0030 -0.0090 0.0030 0.291 
D2 0.0071 0.0056 
CNT2 
Baseline 0.0377 0.0590 
0.0330 -0.0289 0.0948 0.230 
D2 0.0048 0.0045 
OATP1 
Baseline 1.5963 3.5391 
1.5600 -2.1541 5.2741 0.330 
D2 0.0363 0.0208 
OATP3 
Baseline 0.0211 0.0306 
0.0189 -0.0132 0.0510 0.193 
D2 0.0022 0.0047 
OAT-K1 
Baseline 0.3823 0.4696 
-0.2478 -0.7443 0.2486 0.276 
D2 0.6301 0.2410 
MATE 
Baseline 0.0515 0.0509 
-0.2263 -0.4307 -0.0220 0.033 
D2 0.2778 0.2233 
BCRP 
Baseline 1.5526 3.6796 
1.0846 -2.7718 4.9410 0.505 
D2 0.4680 0.5233 
MRP2 
Baseline 0.0023 0.0022 
-0.0087 -0.0142 -0.3264 0.005 
D2 0.0110 0.0058 
MRP3 
Baseline 0.0060 0.0114 
-0.0096 -0.0288 0.0097 0.301 
D2 0.0155 0.0192 
PGP 
Baseline 0.0041 0.0038 
-0.0107 -0.0376 0.0161 0.401 




14. Statistical analysis on effects of HFD-STZ on drug transporters 










values Lower Upper 
OCT1 
C1 0.0278 0.0074 
0.0062 -0.0036 0.0159 0.193 
D1 0.0216 0.0089 
OCT2 
C1 0.8373 0.3593 
0.1127 -0.2311 0.4565 0.489 
D1 0.7246 0.2327 
OCT3 
C1 0.0010 0.0010 
-0.0004 -0.0025 0.0018 0.695 
D1 0.0014 0.0022 
OCTN1 
C1 0.0097 0.0116 
0.0041 -0.0059 0.0140 0.390 
D1 0.0056 0.0050 
OCTN2 
C1 0.0740 0.0458 
0.0119 -0.0332 0.0570 0.576 
D1 0.0621 0.0320 
OAT1 
C1 0.0112 0.0203 
-0.0146 -0.0765 0.0474 0.618 
D1 0.0257 0.0668 
OAT2 
C1 0.0089 0.0055 
0.0025 -0.0027 0.0077 0.310 
D1 0.0064 0.0034 
OAT3 
C1 0.0130 0.0072 
-0.0064 -0.0229 0.0102 0.420 
D1 0.0194 0.0174 
PEPT1 
C1 0.0005 0.0007 
0.0003 -0.0004 0.0011 0.305 
D1 0.0001 0.0003 
PEPT2 
C1 0.1006 0.0614 
0.0262 -0.0288 0.0813 0.373 
D1 0.0744 0.0326 
CNT1 
C1 0.0029 0.0024 
-0.0009 -0.0039 0.0020 0.503 
D1 0.0039 0.0026 
CNT2 
C1 0.0021 0.0027 
-0.0012 -0.0045 0.0021 0.439 
D1 0.0033 0.0028 
OATP1 
C1 0.1211 0.0810 
-0.0102 -0.1639 0.1436 0.888 
D1 0.1312 0.1568 
OATP3 
C1 0.0011 0.0011 
-0.0061 -0.0218 0.0095 0.410 
D1 0.0073 0.0174 
OAT-K1 
C1 0.4565 0.1581 
-0.2091 -0.4849 0.0667 0.124 
D1 0.6656 0.2763 
MATE1 
C1 0.1707 0.1186 
0.0038 -0.1266 0.1343 0.950 
D1 0.1668 0.1050 
BCRP 
C1 0.1232 0.0466 
-0.0415 -0.1127 0.0297 0.228 
D1 0.1647 0.0687 
MRP2 
C1 0.0058 0.0047 
-0.0030 -0.0100 0.0040 0.365 
D1 0.0088 0.0067 
MRP3 
C1 0.0071 0.0061 
0.0025 -0.0041 0.0091 0.431 
D1 0.0046 0.0052 
PGP 
C1 0.0026 0.0022 
-0.0017 -0.0050 0.0016 0.293 





1. Statistical analysis on effects of HFD-STZ on drug transporters 










values Lower Upper 
OCT1 
C2 0.0188 0.0077 
0.0044 -0.0030 0.0117 0.221 
D2 0.0145 0.0049 
OCT2 
C2 0.7496 0.4474 
-0.0199 -0.6000 0.5601 0.941 
D2 0.7695 0.5230 
OCT3 
C2 0.0015 0.0012 
-0.0052 -0.0203 0.0098 0.463 
D2 0.0067 0.0167 
OCTN1 
C2 0.0031 0.0023 
0.0008 -0.0015 0.0032 0.444 
D2 0.0023 0.0017 
OCTN2 
C2 0.0776 0.0817 
-0.0592 -0.1790 0.0606 0.303 
D2 0.1368 0.1140 
OAT1 
C2 0.0017 0.0010 
-0.0088 -0.0305 0.0128 0.393 
D2 0.0105 0.0241 
OAT2 
C2 0.0074 0.0031 
-0.0019 -0.0061 0.0022 0.332 
D2 0.0093 0.0039 
OAT3 
C2 0.0158 0.0121 
-0.0073 -0.0294 0.0148 0.485 
D2 0.0231 0.0223 
PEPT1 
C2 0.0012 0.0008 
-0.0011 -0.0037 0.0014 0.344 
D2 0.0023 0.0027 
PEPT2 
C2 0.0522 0.0151 
-0.0294 -0.0847 0.0259 0.527 
D2 0.0815 0.0602 
CNT1 
C2 0.0061 0.0090 
-0.0010 -0.0095 0.0076 0.809 
D2 0.0071 0.0056 
CNT2 
C2 0.0026 0.0039 
-0.0022 -0.0071 0.0028 0.364 
D2 0.0048 0.0045 
OATP1 
C2 0.0403 0.0337 
0.0040 -0.0277 0.0357 0.789 
D2 0.0363 0.0208 
OATP3 
C2 0.0003 0.0003 
-0.0020 -0.0062 0.0023 0.332 
D2 0.0022 0.0047 
OAT-K1 
C2 0.5478 0.3162 
-0.0823 -0.4057 0.2411 0.589 
D2 0.6301 0.2410 
MATE1 
C2 0.3293 0.2940 
0.0514 -0.2488 0.3517 0.715 
D2 0.2778 0.2233 
BCRP 
C2 0.3570 0.2179 
-0.1111 -0.6097 0.3875 0.636 
D2 0.4680 0.5233 
MRP2 
C2 0.0119 0.0070 
0.0009 -0.0066 0.0083 0.807 
D2 0.0110 0.0058 
MRP3 
C2 0.0119 0.0110 
-0.0037 -0.0229 0.0155 0.682 
D2 0.0155 0.0192 
PGP 
C2 0.0025 0.0016 
-0.0123 -0.0390 0.0144 0.335 
D2 0.0148 0.0297 
 
 
